,coef,coef_graph,coef_combined,coef_combined_zscore,coef_combined2
5-Phosphoribose 1-diphosphate biosynthesis,0.0008979505,2.0,0.0008979505,-0.25646544,0.2432951
A tetrasaccharide linker sequence is required for GAG synthesis,0.026867364,14.0,0.026867364,0.15593149,0.070456065
ABC transporters in lipid homeostasis,0.09726809,11.0,0.09726809,1.2739022,1.0718758
ADP signalling through P2Y purinoceptor 1,0.00766794,19.0,0.00766794,-0.1489573,-0.37565726
ADP signalling through P2Y purinoceptor 12,0.004131522,17.0,0.004131522,-0.20511597,-0.33698344
AKT phosphorylates targets in the cytosol,0.006318696,14.0,0.006318696,-0.17038344,-0.18561296
AKT phosphorylates targets in the nucleus,0.0009256954,9.0,0.0009256954,-0.25602484,-0.045960315
AKT-mediated inactivation of FOXO1A,3.0210136e-05,5.0,3.0210136e-05,-0.27024522,0.10836693
ALKBH2 mediated reversal of alkylation damage,4.367864e-05,2.0,4.367864e-05,-0.27003133,0.23264956
ALKBH3 mediated reversal of alkylation damage,0.00045034732,4.0,0.00045034732,-0.2635734,0.1549741
AMPK inhibits chREBP transcriptional activation activity,0.0010506248,7.0,0.0010506248,-0.25404093,0.0383397
APC truncation mutants are not K63 polyubiquitinated,0.031658374,2.0,0.031658374,0.23201323,0.62661886
APC truncation mutants have impaired AXIN binding,0.17357737,11.0,0.17357737,2.4857013,2.0228105
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1,0.038062178,45.0,0.038062178,0.3337063,-1.0725585
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway,0.0038590957,6.0,0.0038590957,-0.20944214,0.11470931
APOBEC3G mediated resistance to HIV-1 infection,0.00021985808,4.0,0.00021985808,-0.2672336,0.15210183
ARL13B-mediated ciliary trafficking of INPP5E,0.009738979,3.0,0.009738979,-0.11606899,0.3120968
ATF4 activates genes,0.014079001,4.0,0.014079001,-0.047149006,0.32480875
ATF6 (ATF6-alpha) activates chaperone genes,0.05506986,6.0,0.05506986,0.60379,0.7528768
ATP sensitive Potassium channels,7.600374e-05,3.0,7.600374e-05,-0.26951802,0.19168079
AUF1 (hnRNP D0) binds and destabilizes mRNA,0.007737801,34.0,0.007737801,-0.1478479,-0.9953608
AURKA Activation by TPX2,0.00031170077,50.0,0.00031170077,-0.2657751,-1.7498474
AXIN missense mutants destabilize the destruction complex,0.0029682491,11.0,0.0029682491,-0.22358887,-0.10325004
Abacavir metabolism,0.00021451242,3.0,0.00021451242,-0.2673185,0.19340684
Abacavir transmembrane transport,9.717472e-05,2.0,9.717472e-05,-0.26918182,0.2333162
Abasic sugar-phosphate removal via the single-nucleotide replacement pathway,0.0015504451,2.0,0.0015504451,-0.24610373,0.25142625
Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,7.375958e-05,2.0,7.375958e-05,-0.26955366,0.23302439
Acetylation,0.0,1.0,0.0,-0.27072495,0.27347687
Acetylcholine Neurotransmitter Release Cycle,0.00035895192,11.0,0.00035895192,-0.26502478,-0.13576603
Acetylcholine regulates insulin secretion,0.0006622903,7.0,0.0006622903,-0.26020774,0.03350044
Acrosome Reaction,0.0,1.0,0.0,-0.27072495,0.27347687
Activated NOTCH1 Transmits Signal to the Nucleus,0.0032663317,22.0,0.0032663317,-0.21885529,-0.55462307
Activated NTRK2 signals through CDK5,0.0164105,6.0,0.0164105,-0.010124564,0.27111974
Activated NTRK2 signals through FRS2 and FRS3,0.0017845728,8.0,0.0017845728,-0.24238577,0.006114273
Activated NTRK2 signals through FYN,0.00023738173,6.0,0.00023738173,-0.26695532,0.06957699
Activated NTRK2 signals through PI3K,0.018620323,5.0,0.018620323,0.024967657,0.34002927
Activated NTRK2 signals through PLCG1,0.004815303,3.0,0.004815303,-0.19425747,0.25074
Activated NTRK2 signals through RAS,0.019555738,6.0,0.019555738,0.03982214,0.31031442
Activated NTRK3 signals through PI3K,0.03000993,7.0,0.03000993,0.20583574,0.39921862
Activated NTRK3 signals through PLCG1,0.006945385,4.0,0.006945385,-0.16043155,0.23591258
Activated NTRK3 signals through RAS,0.015555883,7.0,0.015555883,-0.023695968,0.21909826
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,0.0024779483,6.0,0.0024779483,-0.23137489,0.09749804
Activation and oligomerization of BAK protein,0.00025703458,3.0,0.00025703458,-0.26664326,0.19393672
Activation of AMPA receptors,0.00041541588,3.0,0.00041541588,-0.26412812,0.19591041
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins,0.07735455,47.0,0.07735455,0.9576732,-0.6656564
Activation of ATR in response to replication stress,0.009408333,27.0,0.009408333,-0.12131968,-0.68494195
Activation of BAD and translocation to mitochondria ,0.00010873916,12.0,0.00010873916,-0.26899818,-0.1802557
Activation of BIM and translocation to mitochondria ,0.0015159461,3.0,0.0015159461,-0.24665159,0.20962474
Activation of BMF and translocation to mitochondria,0.00013874644,4.0,0.00013874644,-0.26852167,0.15109107
Activation of C3 and C5,0.0,1.0,0.0,-0.27072495,0.27347687
Activation of DNA fragmentation factor,0.0022340717,7.0,0.0022340717,-0.23524769,0.053087328
Activation of G protein gated Potassium channels,0.0165009,16.0,0.0165009,-0.008689007,-0.14146973
Activation of Matrix Metalloproteinases,0.0017650252,15.0,0.0017650252,-0.2426962,-0.28373054
Activation of NF-kappaB in B cells,0.001701425,48.0,0.001701425,-0.24370617,-1.6497859
Activation of NOXA and translocation to mitochondria,0.00022407346,4.0,0.00022407346,-0.26716664,0.15215439
Activation of Nicotinic Acetylcholine Receptors,0.033104453,10.0,0.033104453,0.2549771,0.31366652
Activation of PPARGC1A (PGC-1alpha) by phosphorylation,0.002813746,8.0,0.002813746,-0.22604239,0.018939417
Activation of PUMA and translocation to mitochondria,0.0020373608,6.0,0.0020373608,-0.23837146,0.09200761
Activation of RAC1,0.003208126,7.0,0.003208126,-0.2197796,0.0652256
Activation of RAS in B cells,0.008093855,5.0,0.008093855,-0.14219372,0.20885274
Activation of SMO,0.031960968,7.0,0.031960968,0.23681845,0.42353165
Activation of TRKA receptors,0.00061168004,4.0,0.00061168004,-0.26101142,0.15698457
Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.021847839,45.0,0.021847839,0.07622093,-1.2746149
Activation of gene expression by SREBF (SREBP),0.032817945,17.0,0.032817945,0.25042734,0.020494958
Activation of the TFAP2 (AP-2) family of transcription factors,0.00033805042,7.0,0.00033805042,-0.2653567,0.02945989
"Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S",0.037133865,31.0,0.037133865,0.31896457,-0.5049243
Activation of the pre-replicative complex,0.020570815,23.0,0.020570815,0.055941656,-0.3803534
"Activation, myristolyation of BID and translocation to mitochondria",0.00064348115,4.0,0.00064348115,-0.26050642,0.15738085
"Activation, translocation and oligomerization of BAX",0.00033862802,3.0,0.00033862802,-0.2653475,0.19495352
Acyl chain remodeling of CL,0.08539466,7.0,0.08539466,1.0853509,1.0894003
Acyl chain remodeling of DAG and TAG,0.006236337,5.0,0.006236337,-0.1716913,0.18570513
Acyl chain remodelling of PC,0.042855,15.0,0.042855,0.40981674,0.22831576
Acyl chain remodelling of PE,0.117161125,14.0,0.117161125,1.5898056,1.1956598
Acyl chain remodelling of PG,0.004943041,10.0,0.004943041,-0.19222897,-0.037269395
Acyl chain remodelling of PI,0.097991355,10.0,0.097991355,1.2853878,1.1222603
Acyl chain remodelling of PS,0.0070296344,10.0,0.0070296344,-0.15909366,-0.011267137
Adrenaline signalling through Alpha-2 adrenergic receptor,0.00010917116,2.0,0.00010917116,-0.26899132,0.2334657
"Adrenaline,noradrenaline inhibits insulin secretion",0.014436286,22.0,0.014436286,-0.04147528,-0.4154277
Advanced glycosylation endproduct receptor signaling,0.014637846,10.0,0.014637846,-0.038274493,0.08354326
Aflatoxin activation and detoxification,0.00015749311,10.0,0.00015749311,-0.26822397,-0.09690493
Agmatine biosynthesis,0.00087689335,2.0,0.00087689335,-0.2567998,0.24303274
Alpha-defensins,0.0002554327,4.0,0.0002554327,-0.26666868,0.15254515
Alpha-oxidation of phytanate,0.0011516218,6.0,0.0011516218,-0.2524371,0.08096988
Alternative complement activation,0.0031998558,2.0,0.0031998558,-0.21991093,0.27198052
Amine ligand-binding receptors,0.0020275386,20.0,0.0020275386,-0.23852745,-0.48731723
Amino acid transport across the plasma membrane,0.008229832,14.0,0.008229832,-0.14003439,-0.16179717
Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal,0.013193468,54.0,0.013193468,-0.061211362,-1.7548065
Amyloid fiber formation,0.00025759262,34.0,0.00025759262,-0.26663437,-1.088576
Anchoring fibril formation,0.0,1.0,0.0,-0.27072495,0.27347687
Anchoring of the basal body to the plasma membrane,0.049748547,73.0,0.049748547,0.51928705,-2.0853326
Androgen biosynthesis,0.006035606,5.0,0.006035606,-0.17487894,0.18320368
Antagonism of Activin by Follistatin,0.00021317939,4.0,0.00021317939,-0.26733965,0.15201862
"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.002426311,19.0,0.002426311,-0.2321949,-0.4409763
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.04063408,22.0,0.04063408,0.37454835,-0.08896157
Antigen processing: Ubiquitination & Proteasome degradation,0.1054589,207.0,0.0005094633,-0.26263463,-6.9348874
Apoptotic cleavage of cell adhesion  proteins,0.0002033499,7.0,0.0002033499,-0.26749575,0.02778132
Arachidonate production from DAG,0.002073797,4.0,0.002073797,-0.23779286,0.17520486
Aryl hydrocarbon receptor signalling,0.00032500073,7.0,0.00032500073,-0.26556394,0.029297255
Assembly of active LPL and LIPC lipase complexes,0.035504755,12.0,0.035504755,0.29309413,0.26083484
Assembly of the ORC complex at the origin of replication,0.0011571101,6.0,0.0011571101,-0.25234994,0.08103828
Association of TriC/CCT with target proteins during biosynthesis,0.15896274,31.0,0.15896274,2.2536194,1.013257
Astrocytic Glutamate-Glutamine Uptake And Metabolism,0.00083220337,4.0,0.00083220337,-0.2575095,0.15973265
Asymmetric localization of PCP proteins,0.00858716,43.0,0.00858716,-0.13435999,-1.3571208
Attachment of GPI anchor to uPAR,0.007632232,5.0,0.007632232,-0.14952436,0.20310017
Attenuation phase,0.01287831,14.0,0.01287831,-0.0662161,-0.103869766
Autodegradation of Cdh1 by Cdh1:APC/C,0.0587383,43.0,0.0587383,0.6620452,-0.73215795
Axonal growth inhibition (RHOA activation),0.0006659857,5.0,0.0006659857,-0.26014906,0.116289705
Axonal growth stimulation,0.0006904,4.0,0.0006904,-0.25976133,0.15796556
B-WICH complex positively regulates rRNA expression,0.000530522,21.0,0.000530522,-0.26230022,-0.547344
BBSome-mediated cargo-targeting to cilium,0.0016875509,12.0,0.0016875509,-0.24392648,-0.16058119
BDNF activates NTRK2 (TRKB) signaling,9.499986e-05,2.0,9.499986e-05,-0.26921636,0.2332891
BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members,0.00030878818,5.0,0.00030878818,-0.2658214,0.111838445
"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.0071987645,7.0,0.0071987645,-0.15640786,0.11495528
Basigin interactions,0.0031253947,10.0,0.0031253947,-0.22109339,-0.059920166
Beta defensins,3.7079622e-05,22.0,3.7079622e-05,-0.27013615,-0.5948647
Beta-catenin phosphorylation cascade,0.0037334475,12.0,0.0037334475,-0.21143743,-0.13508606
Beta-oxidation of pristanoyl-CoA,0.011849514,6.0,0.011849514,-0.082553476,0.2142826
Beta-oxidation of very long chain fatty acids,0.00024308254,8.0,0.00024308254,-0.26686478,-0.01309513
Bicarbonate transporters,0.0044268207,6.0,0.0044268207,-0.20042661,0.12178406
Binding of TCF/LEF:CTNNB1 to target gene promoters,0.0001292787,8.0,0.0001292787,-0.26867202,-0.014513321
Biogenic amines are oxidatively deaminated to aldehydes by MAOA and MAOB,0.0,1.0,0.0,-0.27072495,0.27347687
"Biosynthesis of A2E, implicated in retinal degradation",0.004221549,2.0,0.004221549,-0.20368634,0.28471246
Biosynthesis of D-series resolvins,0.00036004966,4.0,0.00036004966,-0.26500735,0.15384884
Biosynthesis of DHA-derived sulfido conjugates,0.0,1.0,0.0,-0.27072495,0.27347687
Biosynthesis of DPAn-3 SPMs,0.01387603,3.0,0.01387603,-0.0503722,0.363651
Biosynthesis of DPAn-6 SPMs,0.00012537144,2.0,0.00012537144,-0.26873407,0.23366755
Biosynthesis of E-series 18(R)-resolvins,0.0009222021,4.0,0.0009222021,-0.25608033,0.16085415
Biosynthesis of E-series 18(S)-resolvins,0.0037222258,4.0,0.0037222258,-0.21161564,0.19574691
Biosynthesis of aspirin-triggered D-series resolvins,0.0031717878,4.0,0.0031717878,-0.22035666,0.18888758
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives,0.00081324857,2.0,0.00081324857,-0.2578105,0.24223961
Biosynthesis of maresins,0.0013875819,4.0,0.0013875819,-0.24869004,0.16665353
Biosynthesis of protectins,1.8175742e-05,3.0,1.8175742e-05,-0.27043635,0.19096017
Biotin transport and metabolism,0.009706704,11.0,0.009706704,-0.11658152,-0.019278202
Breakdown of the nuclear lamina,1.2140407e-05,3.0,1.2140407e-05,-0.27053216,0.19088496
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,8.5800486e-05,13.0,8.5800486e-05,-0.26936245,-0.22191314
Butyrophilin (BTN) family interactions,0.024293333,9.0,0.024293333,0.11505563,0.24523754
C6 deamination of adenosine,0.00014174907,2.0,0.00014174907,-0.26847398,0.23387165
CASP8 activity is inhibited,0.002183709,9.0,0.002183709,-0.23604745,-0.03028346
CD209 (DC-SIGN) signaling,0.004451312,16.0,0.004451312,-0.20003767,-0.29162675
CD22 mediated BCR regulation,0.0017055761,5.0,0.0017055761,-0.24364024,0.12924464
CD28 dependent PI3K/Akt signaling,0.009886628,15.0,0.009886628,-0.11372431,-0.18252246
CD28 dependent Vav1 pathway,0.0012663798,9.0,0.0012663798,-0.2506147,-0.04171482
CDC6 association with the ORC:origin complex,3.6051326e-05,7.0,3.6051326e-05,-0.27015245,0.025696518
CDK-mediated phosphorylation and removal of Cdc6,0.00044506893,48.0,0.00044506893,-0.2636572,-1.6654422
CDO in myogenesis,0.00037471566,23.0,0.00037471566,-0.26477444,-0.6320288
CDT1 association with the CDC6:ORC:origin complex,0.00067197625,38.0,0.00067197625,-0.2600539,-1.2488985
CHL1 interactions,0.0010593734,5.0,0.0010593734,-0.253902,0.121191934
CLEC7A (Dectin-1) induces NFAT activation,0.032694127,8.0,0.032694127,0.2484611,0.3912964
CLEC7A/inflammasome pathway,0.012918691,3.0,0.012918691,-0.06557484,0.35172108
COPI-dependent Golgi-to-ER retrograde traffic,0.00017188028,49.0,0.00017188028,-0.26799548,-1.7102182
COPI-independent Golgi-to-ER retrograde traffic,3.2784048e-06,27.0,3.2784048e-06,-0.27067292,-0.8021439
COPI-mediated anterograde transport,0.0139472205,63.0,0.0139472205,-0.049241688,-2.1177583
COPII-mediated vesicle transport,0.30005512,54.0,0.30005512,4.4941807,1.8199452
COX reactions,0.00074287754,2.0,0.00074287754,-0.258928,0.24136266
CREB3 factors activate genes,0.12096384,9.0,0.12096384,1.6501931,1.4499055
CRMPs in Sema3A signaling,0.006572097,11.0,0.006572097,-0.1663594,-0.05834037
CS/DS degradation,0.005178222,8.0,0.005178222,-0.18849427,0.04840455
CTLA4 inhibitory signaling,0.005929394,16.0,0.005929394,-0.17656559,-0.2732075
Ca2+ activated K+ channels,0.0016218465,4.0,0.0016218465,-0.24496989,0.16957285
Ca2+ pathway,0.030731086,43.0,0.030731086,0.2172878,-1.0811722
Calcineurin activates NFAT,0.0008473073,8.0,0.0008473073,-0.25726962,-0.005565532
Calcitonin-like ligand receptors,1.3864679e-05,3.0,1.3864679e-05,-0.27050477,0.19090647
Calmodulin induced events,0.003964739,13.0,0.003964739,-0.2077645,-0.1735754
Calnexin/calreticulin cycle,0.00015454426,21.0,0.00015454426,-0.2682708,-0.5520293
Carboxyterminal post-translational modifications of tubulin,0.10097474,21.0,0.10097474,1.3327641,0.7043504
Cargo concentration in the ER,0.042006634,20.0,0.042006634,0.39634463,0.010885811
Cargo recognition for clathrin-mediated endocytosis,0.0049923244,65.0,0.0049923244,-0.19144633,-2.3120935
Carnitine synthesis,0.049090035,5.0,0.049090035,0.50882983,0.71973026
Caspase-mediated cleavage of cytoskeletal proteins,5.6384943e-05,11.0,5.6384943e-05,-0.26982957,-0.13953651
Catecholamine biosynthesis,0.0011068379,4.0,0.0011068379,-0.25314826,0.163155
Cation-coupled Chloride cotransporters,0.001786701,3.0,0.001786701,-0.24235196,0.2129988
Cell redox homeostasis,0.0,1.0,0.0,-0.27072495,0.27347687
Cellular hexose transport,0.006836954,9.0,0.006836954,-0.16215344,0.027703362
Centrosome maturation,0.00013790013,57.0,0.00013790013,-0.26853508,-2.0416145
Ceramide signalling,0.004441127,2.0,0.004441127,-0.20019941,0.28744873
ChREBP activates metabolic gene expression,5.395052e-07,5.0,5.395052e-07,-0.2707164,0.1079972
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex,0.009896862,7.0,0.009896862,-0.11356179,0.14857787
Cholesterol biosynthesis via desmosterol,0.0020780803,2.0,0.0020780803,-0.23772484,0.25800142
Cholesterol biosynthesis via lathosterol,0.0055645257,2.0,0.0055645257,-0.18235974,0.30144808
Choline catabolism,0.015878547,3.0,0.015878547,-0.018572029,0.38860556
Chondroitin sulfate biosynthesis,0.048063427,12.0,0.048063427,0.49252713,0.4173359
Chylomicron assembly,1.4212528e-05,5.0,1.4212528e-05,-0.2704993,0.10816756
Chylomicron clearance,0.00012484302,2.0,0.00012484302,-0.26874244,0.23366101
Chylomicron remodeling,0.004032874,6.0,0.004032874,-0.2066825,0.11687488
Citric acid cycle (TCA cycle),0.0007421743,19.0,0.0007421743,-0.25893915,-0.46196327
Class C/3 (Metabotropic glutamate/pheromone receptors),0.0141116185,18.0,0.0141116185,-0.04663103,-0.2539872
Classical Kir channels,0.001943853,3.0,0.001943853,-0.23985639,0.21495715
Cleavage of Growing Transcript in the Termination Region ,0.03736055,53.0,0.03736055,0.32256433,-1.4122747
Cleavage of the damaged purine,0.00059087534,3.0,0.00059087534,-0.2613418,0.1980969
Cleavage of the damaged pyrimidine ,0.008011182,8.0,0.008011182,-0.14350659,0.08370772
"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.025494576,14.0,0.025494576,0.13413148,0.053348947
Coenzyme A biosynthesis,0.00011958125,4.0,0.00011958125,-0.268826,0.15085223
Cohesin Loading onto Chromatin,0.008913372,9.0,0.008913372,-0.12917972,0.053578824
Collagen chain trimerization,0.30690646,21.0,0.30690646,4.6029806,3.270587
Collagen degradation,0.00029776472,15.0,0.00029776472,-0.26599643,-0.30201492
Common Pathway of Fibrin Clot Formation,0.005455942,13.0,0.005455942,-0.18408406,-0.15499265
Complex I biogenesis,0.060899395,25.0,0.060899395,0.69636357,0.03946164
Condensation of Prometaphase Chromosomes,0.0035481825,5.0,0.0035481825,-0.21437946,0.15220645
Condensation of Prophase Chromosomes,0.0003946702,7.0,0.0003946702,-0.26445755,0.030165464
Conjugation of carboxylic acids,8.150101e-05,5.0,8.150101e-05,-0.2694307,0.109006114
Constitutive Signaling by AKT1 E17K in Cancer,0.013302981,22.0,0.013302981,-0.059472278,-0.4295505
Constitutive Signaling by Aberrant PI3K in Cancer,0.026655193,46.0,0.026655193,0.15256222,-1.2560792
Constitutive Signaling by EGFRvIII,0.1682234,13.0,0.1682234,2.4006796,1.8733484
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants,0.09653532,16.0,0.09653532,1.2622657,0.85588616
Constitutive Signaling by NOTCH1 HD Domain Mutants,0.059471432,11.0,0.059471432,0.6736874,0.60086936
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,0.00706013,41.0,0.00706013,-0.15860939,-1.2934068
Constitutive Signaling by NOTCH1 PEST Domain Mutants,0.0011033188,41.0,0.0011033188,-0.25320414,-1.3676381
Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant,0.016112639,5.0,0.016112639,-0.0148546295,0.3087795
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase,0.016501546,14.0,0.016501546,-0.008678743,-0.05871848
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding,0.0012589893,26.0,0.0012589893,-0.2507321,-0.74512416
Creatine metabolism,0.10067981,7.0,0.10067981,1.3280807,1.2798775
Creation of C4 and C2 activators,0.010025163,5.0,0.010025163,-0.11152436,0.2329199
Cristae formation,0.026022108,9.0,0.026022108,0.14250876,0.26678085
Cross-presentation of particulate exogenous antigens (phagosomes),0.018156169,4.0,0.018156169,0.017596839,0.37561676
Cross-presentation of soluble exogenous antigens (endosomes),0.014923778,30.0,0.014923778,-0.033733852,-0.7403256
Crosslinking of collagen fibrils,0.013783309,4.0,0.013783309,-0.051844627,0.32112396
Cyclin A/B1/B2 associated events during G2/M transition,6.2687086e-06,13.0,6.2687086e-06,-0.27062544,-0.22290426
Cyclin D associated events in G1,0.23236337,33.0,0.23236337,3.419229,1.8452023
Cysteine formation from homocysteine,0.0013327643,3.0,0.0013327643,-0.24956055,0.20734201
Cytochrome c-mediated apoptotic response,0.009544172,6.0,0.009544172,-0.119162545,0.1855544
Cytosolic iron-sulfur cluster assembly,7.858845e-05,10.0,7.858845e-05,-0.26947698,-0.0978882
Cytosolic tRNA aminoacylation,0.008203665,7.0,0.008203665,-0.14044994,0.12747794
DAP12 signaling,0.00241919,21.0,0.00241919,-0.23230797,-0.5238082
DCC mediated attractive signaling,0.017366363,13.0,0.017366363,0.005054636,-0.00656989
DEx/H-box helicases activate type I IFN and inflammatory cytokines production ,0.0025219074,7.0,0.0025219074,-0.23067681,0.056674227
DNA Damage Recognition in GG-NER,0.0117361415,21.0,0.0117361415,-0.08435385,-0.4077042
DNA methylation,0.00011091368,4.0,0.00011091368,-0.26896366,0.15074421
DNA replication initiation,3.964154e-06,6.0,3.964154e-06,-0.270662,0.06666826
DSCAM interactions,0.0029018102,9.0,0.0029018102,-0.22464393,-0.021334784
Deactivation of the beta-catenin transactivating complex,0.03247784,30.0,0.03247784,0.24502644,-0.52157414
Deadenylation of mRNA,0.004452135,17.0,0.004452135,-0.2000246,-0.33298808
Dectin-1 mediated noncanonical NF-kB signaling,0.03822882,38.0,0.03822882,0.3363526,-0.78088063
Dectin-2 family,0.021471448,12.0,0.021471448,0.07024381,0.085957594
Defective ABCA1 causes Tangier disease,0.0,1.0,0.0,-0.27072495,0.27347687
Defective ABCA12 causes autosomal recessive congenital ichthyosis type 4B,0.0,1.0,0.0,-0.27072495,0.27347687
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction 3 (SMDP3),0.0,1.0,0.0,-0.27072495,0.27347687
Defective ABCA3 causes pulmonary surfactant metabolism dysfunction type 3 (SMDP3),0.0,1.0,0.0,-0.27072495,0.27347687
Defective ABCB11 causes progressive familial intrahepatic cholestasis 2 and benign recurrent intrahepatic cholestasis 2,0.0,1.0,0.0,-0.27072495,0.27347687
"Defective ABCB4 causes progressive familial intrahepatic cholestasis 3, intrahepatic cholestasis of pregnancy 3 and gallbladder disease 1",0.0,1.0,0.0,-0.27072495,0.27347687
Defective ABCB6 causes isolated colobomatous microphthalmia 7 (MCOPCB7),0.0,1.0,0.0,-0.27072495,0.27347687
Defective ABCC2 causes Dubin-Johnson syndrome,0.0,1.0,0.0,-0.27072495,0.27347687
Defective ABCC6 causes pseudoxanthoma elasticum (PXE),0.0,1.0,0.0,-0.27072495,0.27347687
Defective ABCC8 can cause hypoglycemias and hyperglycemias,3.3176855e-07,2.0,3.3176855e-07,-0.2707197,0.23210938
"Defective ABCC9 causes dilated cardiomyopathy 10, familial atrial fibrillation 12 and hypertrichotic osteochondrodysplasia",0.0,1.0,0.0,-0.27072495,0.27347687
Defective ABCD1 causes adrenoleukodystrophy (ALD),0.0,1.0,0.0,-0.27072495,0.27347687
"Defective ABCD4 causes methylmalonic aciduria and homocystinuria, cblj type (MAHCJ)",0.0,2.0,0.0,-0.27072495,0.23210524
Defective ABCG5 causes sitosterolemia,0.0,1.0,0.0,-0.27072495,0.27347687
Defective ABCG8 causes gallbladder disease 4 and sitosterolemia,0.0,1.0,0.0,-0.27072495,0.27347687
Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD),0.0008071092,3.0,0.0008071092,-0.25790802,0.20079151
Defective ACY1 causes encephalopathy,0.0,1.0,0.0,-0.27072495,0.27347687
Defective AHCY causes Hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency (HMAHCHD),0.0,1.0,0.0,-0.27072495,0.27347687
Defective ALG1 causes ALG1-CDG (CDG-1k),0.0,1.0,0.0,-0.27072495,0.27347687
Defective ALG11 causes ALG11-CDG (CDG-1p),0.0,1.0,0.0,-0.27072495,0.27347687
Defective ALG12 causes ALG12-CDG (CDG-1g),0.0,1.0,0.0,-0.27072495,0.27347687
Defective ALG14 causes congenital myasthenic syndrome (ALG14-CMS),0.0,1.0,0.0,-0.27072495,0.27347687
Defective ALG2 causes ALG2-CDG (CDG-1i),0.0,1.0,0.0,-0.27072495,0.27347687
Defective ALG3 causes ALG3-CDG (CDG-1d),0.0,1.0,0.0,-0.27072495,0.27347687
Defective ALG6 causes ALG6-CDG (CDG-1c),0.0,1.0,0.0,-0.27072495,0.27347687
Defective ALG8 causes ALG8-CDG (CDG-1h),0.0,1.0,0.0,-0.27072495,0.27347687
Defective ALG9 causes ALG9-CDG (CDG-1l),0.0,1.0,0.0,-0.27072495,0.27347687
Defective AMN causes hereditary megaloblastic anemia 1,0.0,1.0,0.0,-0.27072495,0.27347687
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),2.5308511e-06,3.0,2.5308511e-06,-0.27068478,0.19076522
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),2.5308511e-06,2.0,2.5308511e-06,-0.27068478,0.23213679
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),1.6635144e-07,3.0,1.6635144e-07,-0.27072233,0.19073573
Defective AVP causes neurohypophyseal diabetes insipidus (NDI),1.6635144e-07,2.0,1.6635144e-07,-0.27072233,0.2321073
Defective B3GALT6 causes EDSP2 and SEMDJL1,0.00066668994,9.0,0.00066668994,-0.2601379,-0.049187955
Defective B3GALTL causes Peters-plus syndrome (PpS),0.0001252615,11.0,0.0001252615,-0.2687358,-0.1386782
Defective B3GAT3 causes JDSSDHD,0.0008728636,9.0,0.0008728636,-0.2568638,-0.04661869
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),1.1170888e-05,3.0,1.1170888e-05,-0.27054757,0.19087288
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),1.1170888e-05,1.0,1.1170888e-05,-0.27054757,0.27361608
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,3.0,0.0,-0.27072495,0.19073367
Defective B4GALT1 causes B4GALT1-CDG (CDG-2d),0.0,1.0,0.0,-0.27072495,0.27347687
"Defective B4GALT7 causes EDS, progeroid type",0.0017045797,9.0,0.0017045797,-0.24365607,-0.036254182
Defective BTD causes biotidinase deficiency,0.0,1.0,0.0,-0.27072495,0.27347687
Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS),0.00036159533,7.0,0.00036159533,-0.2649828,0.029753309
Defective CD320 causes methylmalonic aciduria,0.0013975226,3.0,0.0013975226,-0.24853218,0.20814902
Defective CFTR causes cystic fibrosis,0.00024307049,40.0,0.00024307049,-0.266865,-1.3369865
"Defective CHST14 causes EDS, musculocontractural type",7.3851965e-08,2.0,7.3851965e-08,-0.2707238,0.23210618
Defective CHST3 causes SEDCJD,1.7090739e-11,2.0,1.7090739e-11,-0.27072495,0.23210524
Defective CHST6 causes MCDC1,0.004193618,3.0,0.004193618,-0.20412989,0.24299279
Defective CHSY1 causes TPBS,6.667364e-07,2.0,6.667364e-07,-0.27071437,0.23211356
Defective CP causes aceruloplasminemia (ACERULOP),0.0,1.0,0.0,-0.27072495,0.27347687
Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4),4.756072e-06,3.0,4.756072e-06,-0.27064946,0.19079292
Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5),1.487392e-05,3.0,1.487392e-05,-0.27048877,0.19091903
Defective CUBN causes hereditary megaloblastic anemia 1,0.0,1.0,0.0,-0.27072495,0.27347687
"Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)",0.00017661019,3.0,0.00017661019,-0.26792037,0.19293451
Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4),0.0,1.0,0.0,-0.27072495,0.27347687
Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency),0.0,1.0,0.0,-0.27072495,0.27347687
Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5),0.0,1.0,0.0,-0.27072495,0.27347687
Defective CYP19A1 causes Aromatase excess syndrome (AEXS),0.0,1.0,0.0,-0.27072495,0.27347687
Defective CYP1B1 causes Glaucoma,0.0,1.0,0.0,-0.27072495,0.27347687
Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3),0.0,1.0,0.0,-0.27072495,0.27347687
"Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)",0.0,1.0,0.0,-0.27072495,0.27347687
Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA),0.0,1.0,0.0,-0.27072495,0.27347687
Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4),0.0,1.0,0.0,-0.27072495,0.27347687
Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX),0.0,1.0,0.0,-0.27072495,0.27347687
Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A),0.0,1.0,0.0,-0.27072495,0.27347687
Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B),0.0,1.0,0.0,-0.27072495,0.27347687
"Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)",0.0,1.0,0.0,-0.27072495,0.27347687
"Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)",0.0,1.0,0.0,-0.27072495,0.27347687
"Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)",0.0,1.0,0.0,-0.27072495,0.27347687
Defective DHDDS causes retinitis pigmentosa 59,0.0,1.0,0.0,-0.27072495,0.27347687
Defective DOLK causes DOLK-CDG (CDG-1m),0.0,1.0,0.0,-0.27072495,0.27347687
Defective DPAGT1 causes DPAGT1-CDG (CDG-1j) and CMSTA2,0.0,1.0,0.0,-0.27072495,0.27347687
Defective DPM1 causes DPM1-CDG (CDG-1e),0.0,1.0,0.0,-0.27072495,0.27347687
Defective DPM2 causes DPM2-CDG (CDG-1u),0.0,1.0,0.0,-0.27072495,0.27347687
Defective DPM3 causes DPM3-CDG (CDG-1o),0.0,1.0,0.0,-0.27072495,0.27347687
"Defective EXT1 causes exostoses 1, TRPS2 and CHDS",0.0028830206,8.0,0.0028830206,-0.2249423,0.019802688
Defective EXT2 causes exostoses 2,0.0028788657,8.0,0.0028788657,-0.2250083,0.019750902
Defective FMO3 causes Trimethylaminuria (TMAU),0.0,1.0,0.0,-0.27072495,0.27347687
Defective GALE can cause Epimerase-deficiency galactosemia (EDG),0.0,1.0,0.0,-0.27072495,0.27347687
Defective GALK1 can cause Galactosemia II (GALCT2),0.0,1.0,0.0,-0.27072495,0.27347687
Defective GALNT12 causes colorectal cancer 1 (CRCS1),0.00065314636,7.0,0.00065314636,-0.26035294,0.03338648
Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC),0.00014456731,7.0,0.00014456731,-0.26842922,0.027048789
Defective GALT can cause Galactosemia,0.0,1.0,0.0,-0.27072495,0.27347687
Defective GCK causes maturity-onset diabetes of the young 2 (MODY2),0.0,1.0,0.0,-0.27072495,0.27347687
Defective GCLC causes Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency (HAGGSD),0.0,1.0,0.0,-0.27072495,0.27347687
Defective GFPT1 causes CMSTA1,0.0,1.0,0.0,-0.27072495,0.27347687
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.27072495,0.27347687
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.27072495,0.27347687
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.27072495,0.27347687
Defective GGT1 causes Glutathionuria (GLUTH),0.0,1.0,0.0,-0.27072495,0.27347687
Defective GIF causes intrinsic factor deficiency,0.0,1.0,0.0,-0.27072495,0.27347687
"Defective GNE causes sialuria, Nonaka myopathy and inclusion body myopathy 2",0.0,1.0,0.0,-0.27072495,0.27347687
Defective GSS causes Glutathione synthetase deficiency (GSS deficiency),0.0,1.0,0.0,-0.27072495,0.27347687
Defective HEXA causes GM2G1,0.0,1.0,0.0,-0.27072495,0.27347687
Defective HEXB causes GM2G2,0.0,1.0,0.0,-0.27072495,0.27347687
Defective HK1 causes hexokinase deficiency (HK deficiency),0.0,1.0,0.0,-0.27072495,0.27347687
Defective HLCS causes multiple carboxylase deficiency,0.0067459582,6.0,0.0067459582,-0.16359846,0.15068421
Defective LARGE causes MDDGA6 and MDDGB6,0.0,1.0,0.0,-0.27072495,0.27347687
Defective LFNG causes SCDO3,0.00028740268,4.0,0.00028740268,-0.266161,0.15294357
Defective LMBRD1 causes methylmalonic aciduria and homocystinuria type cblF,0.0,1.0,0.0,-0.27072495,0.27347687
Defective MAN1B1 causes MRT15,0.0,1.0,0.0,-0.27072495,0.27347687
Defective MAOA causes Brunner syndrome (BRUNS),0.0,1.0,0.0,-0.27072495,0.27347687
Defective MAT1A causes Methionine adenosyltransferase deficiency (MATD),0.0,1.0,0.0,-0.27072495,0.27347687
Defective MGAT2 causes MGAT2-CDG (CDG-2a),0.0,1.0,0.0,-0.27072495,0.27347687
Defective MMAA causes methylmalonic aciduria type cblA,0.00011349703,2.0,0.00011349703,-0.26892263,0.2335196
Defective MMAB causes methylmalonic aciduria type cblB,0.0,1.0,0.0,-0.27072495,0.27347687
Defective MMACHC causes methylmalonic aciduria and homocystinuria type cblC,4.9551418e-05,2.0,4.9551418e-05,-0.26993808,0.23272273
Defective MMADHC causes methylmalonic aciduria and homocystinuria type cblD,0.007797504,3.0,0.007797504,-0.14689982,0.28790295
Defective MOGS causes MOGS-CDG (CDG-2b),0.0,1.0,0.0,-0.27072495,0.27347687
Defective MPDU1 causes MPDU1-CDG (CDG-1f),0.0,1.0,0.0,-0.27072495,0.27347687
Defective MPI causes MPI-CDG (CDG-1b),0.0,1.0,0.0,-0.27072495,0.27347687
Defective MTR causes methylmalonic aciduria and homocystinuria type cblG,0.007385802,3.0,0.007385802,-0.15343769,0.28277245
Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE,4.6157576e-05,3.0,4.6157576e-05,-0.26999196,0.19130889
Defective MUT causes methylmalonic aciduria mut type,0.0,1.0,0.0,-0.27072495,0.27347687
Defective Mismatch Repair Associated With MLH1,6.228099e-05,3.0,6.228099e-05,-0.26973593,0.1915098
Defective Mismatch Repair Associated With MSH2,0.004631094,3.0,0.004631094,-0.19718271,0.24844445
Defective Mismatch Repair Associated With MSH3,0.0007437865,2.0,0.0007437865,-0.25891358,0.24137399
Defective Mismatch Repair Associated With MSH6,0.00054035324,2.0,0.00054035324,-0.2621441,0.2388389
Defective Mismatch Repair Associated With PMS2,0.0021860765,3.0,0.0021860765,-0.23600985,0.21797566
Defective NEU1 causes sialidosis,0.0,1.0,0.0,-0.27072495,0.27347687
Defective OPLAH causes 5-oxoprolinase deficiency (OPLAHD),0.0,1.0,0.0,-0.27072495,0.27347687
Defective PAPSS2 causes SEMD-PA,0.0,1.0,0.0,-0.27072495,0.27347687
Defective PGM1 causes PGM1-CDG (CDG1t),0.0,1.0,0.0,-0.27072495,0.27347687
Defective PMM2 causes PMM2-CDG (CDG-1a),0.0,1.0,0.0,-0.27072495,0.27347687
"Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3",7.7996425e-05,2.0,7.7996425e-05,-0.26948637,0.23307721
"Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1",0.00019302098,2.0,0.00019302098,-0.26765978,0.23451059
"Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2",0.00025444708,2.0,0.00025444708,-0.26668432,0.23527604
Defective RFT1 causes RFT1-CDG (CDG-1n),0.0,1.0,0.0,-0.27072495,0.27347687
Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SFTPA2 causes idiopathic pulmonary fibrosis (IPF),0.0,1.0,0.0,-0.27072495,0.27347687
"Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1)",0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC12A1 causes Bartter syndrome 1 (BS1),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC12A3 causes Gitelman syndrome (GS),0.0,1.0,0.0,-0.27072495,0.27347687
"Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN)",0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC17A5 causes Salla disease (SD) and ISSD,0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC1A3 causes episodic ataxia 6 (EA6),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC22A12 causes renal hypouricemia 1 (RHUC1),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC24A1 causes congenital stationary night blindness 1D (CSNB1D),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC26A2 causes chondrodysplasias,0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC26A4 causes Pendred syndrome (PDS),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC27A4 causes ichthyosis prematurity syndrome (IPS),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC2A10 causes arterial tortuosity syndrome (ATS),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC2A2 causes Fanconi-Bickel syndrome (FBS),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC2A9 causes hypouricemia renal 2 (RHUC2),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC33A1 causes spastic paraplegia 42 (SPG42),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC35A2 causes congenital disorder of glycosylation 2M (CDG2M),0.0,1.0,0.0,-0.27072495,0.27347687
"Defective SLC35A3 causes arthrogryposis, mental retardation, and seizures (AMRS)",0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC35C1 causes congenital disorder of glycosylation 2C (CDG2C),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC35D1 causes Schneckenbecken dysplasia (SCHBCKD),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG),0.0,1.0,0.0,-0.27072495,0.27347687
"Defective SLC39A4 causes acrodermatitis enteropathica, zinc-deficiency type (AEZ)",0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC3A1 causes cystinuria (CSNU),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.0,1.0,0.0,-0.27072495,0.27347687
"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0,1.0,0.0,-0.27072495,0.27347687
"Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA)",0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC5A2 causes renal glucosuria (GLYS1),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC5A5 causes thyroid dyshormonogenesis 1 (TDH1),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria,0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A19 causes Hartnup disorder (HND),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A2 causes orthostatic intolerance (OI),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC6A5 causes hyperekplexia 3 (HKPX3),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC7A9 causes cystinuria (CSNU),0.0,1.0,0.0,-0.27072495,0.27347687
"Defective SLC9A6 causes  X-linked, syndromic mental retardation,, Christianson type (MRXSCH)",0.0,1.0,0.0,-0.27072495,0.27347687
Defective SLC9A9 causes autism 16 (AUTS16),0.0,1.0,0.0,-0.27072495,0.27347687
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.003688374,2.0,0.003688374,-0.21215321,0.27806824
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.003688374,1.0,0.003688374,-0.21215321,0.3194399
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,2.0,0.0,-0.27072495,0.23210524
"Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0,1.0,0.0,-0.27072495,0.27347687
"Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR)",0.0012982389,2.0,0.0012982389,-0.25010878,0.24828336
"Defective SLCO2A1 causes primary, autosomal recessive hypertrophic osteoarthropathy 2 (PHOAR2)",0.0,1.0,0.0,-0.27072495,0.27347687
Defective SRD5A3 causes SRD5A3-CDG (CDG-1q) and KHRZ,0.0,1.0,0.0,-0.27072495,0.27347687
Defective ST3GAL3 causes MCT12 and EIEE15,0.0003368424,3.0,0.0003368424,-0.26537588,0.19493127
Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD),0.0,1.0,0.0,-0.27072495,0.27347687
Defective TCN2 causes hereditary megaloblastic anemia,0.0029653327,2.0,0.0029653327,-0.22363518,0.269058
Defective TPMT causes Thiopurine S-methyltransferase deficiency (TPMT deficiency),0.0,1.0,0.0,-0.27072495,0.27347687
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC),2.429421e-06,2.0,2.429421e-06,-0.2706864,0.2321355
Defective UGT1A1 causes hyperbilirubinemia,0.0,1.0,0.0,-0.27072495,0.27347687
Defective UGT1A4 causes hyperbilirubinemia,0.0,1.0,0.0,-0.27072495,0.27347687
Defective pro-SFTPB causes pulmonary surfactant metabolism dysfunction 1 (SMDP1) and respiratory distress syndrome (RDS),0.003785112,4.0,0.003785112,-0.210617,0.19653057
Defective pro-SFTPC causes pulmonary surfactant metabolism dysfunction 2 (SMDP2) and respiratory distress syndrome (RDS),4.760794e-05,2.0,4.760794e-05,-0.26996896,0.23269852
Degradation of AXIN,0.013774711,38.0,0.013774711,-0.051981162,-1.0856177
Degradation of DVL,0.058696255,38.0,0.058696255,0.66137755,-0.52582395
Degradation of GABA,0.0070516127,2.0,0.0070516127,-0.15874463,0.31997955
Degradation of GLI1 by the proteasome,0.0141014485,40.0,0.0141014485,-0.046792533,-1.1642891
Degradation of GLI2 by the proteasome,0.0015947056,39.0,0.0015947056,-0.24540088,-1.2787714
Deletions in the AMER1 gene destabilize the destruction complex,0.0013205931,2.0,0.0013205931,-0.24975382,0.24856192
Deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling,0.00048721003,2.0,0.00048721003,-0.26298803,0.23817666
Deposition of new CENPA-containing nucleosomes at the centromere,0.0007851076,16.0,0.0007851076,-0.2582574,-0.33731347
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models,0.015893565,16.0,0.015893565,-0.018333534,-0.14903809
Dermatan sulfate biosynthesis,0.08483257,4.0,0.08483257,1.076425,1.2065105
Detoxification of Reactive Oxygen Species,0.2141661,16.0,0.2141661,3.1302545,2.3217525
Digestion of dietary carbohydrate,0.002654497,7.0,0.002654497,-0.2285713,0.058326494
Digestion of dietary lipid,0.00089580624,7.0,0.00089580624,-0.25649947,0.036410417
Dimerization of procaspase-8,0.00019250276,8.0,0.00019250276,-0.267668,-0.0137254475
Disassembly of the destruction complex and recruitment of AXIN to the membrane,0.031670563,23.0,0.031670563,0.23220679,-0.24203289
Disinhibition of SNARE formation,0.0018534744,3.0,0.0018534744,-0.2412916,0.2138309
Displacement of DNA glycosylase by APEX1,0.023241347,9.0,0.023241347,0.09834997,0.23212813
Dissolution of Fibrin Clot,0.025101867,5.0,0.025101867,0.12789522,0.42079958
Dopamine Neurotransmitter Release Cycle,0.10467853,11.0,0.10467853,1.3915807,1.1642215
Downregulation of ERBB2:ERBB3 signaling,8.428384e-05,12.0,8.428384e-05,-0.26938653,-0.18056044
Downregulation of ERBB4 signaling,0.006533169,8.0,0.006533169,-0.16697757,0.065289326
Downregulation of SMAD2/3:SMAD4 transcriptional activity,0.0006231278,19.0,0.0006231278,-0.26082963,-0.46344683
Downregulation of TGF-beta receptor signaling,0.00016176148,21.0,0.00016176148,-0.26815617,-0.55193937
Downstream TCR signaling,0.011866315,58.0,0.011866315,-0.08228668,-1.9368314
Downstream signal transduction,5.3659287e-06,25.0,5.3659287e-06,-0.27063975,-0.71937466
Downstream signaling of activated FGFR1,0.002622142,22.0,0.002622142,-0.22908507,-0.5626507
Downstream signaling of activated FGFR2,0.042830016,21.0,0.042830016,0.40942004,-0.020225117
Downstream signaling of activated FGFR3,0.025411243,19.0,0.025411243,0.13280815,-0.15454753
Downstream signaling of activated FGFR4,8.6419204e-05,22.0,8.6419204e-05,-0.2693526,-0.59424984
Dual Incision in GG-NER,0.04753541,33.0,0.04753541,0.48414212,-0.45804772
Dual incision in TC-NER,0.015597404,51.0,0.015597404,-0.023036608,-1.6007348
E2F mediated regulation of DNA replication,0.062305655,15.0,0.062305655,0.7186951,0.4707019
E3 ubiquitin ligases ubiquitinate target proteins,0.060495462,32.0,0.060495462,0.6899491,-0.25517324
ECM proteoglycans,0.031769346,24.0,0.031769346,0.23377548,-0.28217345
EGFR downregulation,0.00052013126,18.0,0.00052013126,-0.26246524,-0.4233587
EGFR interacts with phospholipase C-gamma,0.0003023598,3.0,0.0003023598,-0.26592347,0.19450156
EPH-ephrin mediated repulsion of cells,0.01374062,33.0,0.01374062,-0.052522533,-0.8791845
EPHA-mediated growth cone collapse,0.0013813594,12.0,0.0013813594,-0.24878883,-0.16439681
EPHB-mediated forward signaling,0.0069792867,29.0,0.0069792867,-0.15989318,-0.797955
ER-Phagosome pathway,0.0076924353,48.0,0.0076924353,-0.1485683,-1.5751286
ERBB2 Activates PTK6 Signaling,0.0027305146,9.0,0.0027305146,-0.22736411,-0.023469394
ERBB2 Regulates Cell Motility,0.00084497477,10.0,0.00084497477,-0.2573067,-0.08833783
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.00031067553,12.0,0.00031067553,-0.2657914,-0.17773922
Early Phase of HIV Life Cycle,9.6275726e-05,8.0,9.6275726e-05,-0.2691961,-0.014924586
Eicosanoid ligand-binding receptors,0.001086393,3.0,0.001086393,-0.25347292,0.20427184
Eicosanoids,0.000540095,7.0,0.000540095,-0.2621482,0.031977694
Electric Transmission Across Gap Junctions,0.0039523193,4.0,0.0039523193,-0.20796174,0.19861422
Electron transport from NADPH to Ferredoxin,0.008172361,3.0,0.008172361,-0.14094704,0.29257426
Elevation of cytosolic Ca2+ levels,0.02543429,5.0,0.02543429,0.13317412,0.4249421
Endogenous sterols,0.025198054,12.0,0.025198054,0.12942268,0.13239701
Endosomal Sorting Complex Required For Transport (ESCRT),0.002854799,24.0,0.002854799,-0.22539046,-0.6424947
Endosomal/Vacuolar pathway,0.0075558433,8.0,0.0075558433,-0.1507374,0.07803347
Energy dependent regulation of mTOR by LKB1-AMPK,0.0025987308,25.0,0.0025987308,-0.22945686,-0.68705726
Entry of Influenza Virion into Host Cell via Endocytosis,0.0,1.0,0.0,-0.27072495,0.27347687
Enzymatic degradation of Dopamine by monoamine oxidase,2.7200577e-09,2.0,2.7200577e-09,-0.27072492,0.23210527
Enzymatic degradation of dopamine by COMT,2.3097144e-07,2.0,2.3097144e-07,-0.2707213,0.23210812
Ephrin signaling,0.0017084415,13.0,0.0017084415,-0.24359474,-0.20169246
Erythrocytes take up carbon dioxide and release oxygen,0.0004888455,8.0,0.0004888455,-0.26296204,-0.010032535
Erythrocytes take up oxygen and release carbon dioxide,0.00011916462,4.0,0.00011916462,-0.26883262,0.15084705
Essential fructosuria,0.0,1.0,0.0,-0.27072495,0.27347687
Essential pentosuria,0.0,1.0,0.0,-0.27072495,0.27347687
Establishment of Sister Chromatid Cohesion,0.0012538453,8.0,0.0012538453,-0.25081378,-0.0004994275
Estrogen biosynthesis,0.0017442644,3.0,0.0017442644,-0.24302587,0.21246997
Estrogen-dependent gene expression,0.028822685,68.0,0.028822685,0.18698218,-2.139244
Ethanol oxidation,0.012977761,6.0,0.012977761,-0.064636804,0.22834235
Eukaryotic Translation Termination,0.029710194,35.0,0.029710194,0.20107593,-0.76292133
Export of Viral Ribonucleoproteins from Nucleus,0.0038910708,3.0,0.0038910708,-0.20893435,0.23922259
Extrinsic Pathway of Fibrin Clot Formation,0.0007337289,4.0,0.0007337289,-0.25907326,0.15850551
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis,8.946265e-05,37.0,8.946265e-05,-0.26930428,-1.2147859
FCERI mediated Ca+2 mobilization,0.0016245991,19.0,0.0016245991,-0.24492617,-0.4509669
FCERI mediated MAPK activation,0.0003676653,21.0,0.0003676653,-0.2648864,-0.54937345
FCERI mediated NF-kB activation,0.008246876,55.0,0.008246876,-0.13976373,-1.8578206
FCGR activation,0.0070670177,7.0,0.0070670177,-0.15850002,0.11331351
FGFR1 ligand binding and activation,0.00040059598,11.0,0.00040059598,-0.26436347,-0.13524708
FGFR1 mutant receptor activation,0.009344422,23.0,0.009344422,-0.12233459,-0.52025205
FGFR2 alternative splicing,0.04623191,19.0,0.04623191,0.46344247,0.10491107
FGFR2 ligand binding and activation,0.008044171,10.0,0.008044171,-0.1429827,0.0013756008
FGFR2 mutant receptor activation,0.018504832,21.0,0.018504832,0.023133643,-0.32335556
FGFR3 ligand binding and activation,0.0009098838,8.0,0.0009098838,-0.25627592,-0.0047857314
FGFR4 ligand binding and activation,0.0006573699,11.0,0.0006573699,-0.26028585,-0.13204727
FGFR4 mutant receptor activation,0.0026352804,2.0,0.0026352804,-0.22887644,0.26494503
FGFRL1 modulation of FGFR1 signaling,0.00011525008,8.0,0.00011525008,-0.2688948,-0.014688147
FMO oxidises nucleophiles,2.5292025e-05,2.0,2.5292025e-05,-0.2703233,0.23242043
Fanconi Anemia Pathway,0.11224742,25.0,0.11224742,1.5117755,0.6793396
FasL/ CD95L signaling,9.5179144e-05,4.0,9.5179144e-05,-0.2692135,0.15054815
Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion,0.004044836,7.0,0.004044836,-0.20649256,0.07565234
Fatty acids,0.0023095938,6.0,0.0023095938,-0.23404837,0.09540007
Fibronectin matrix formation,0.010432665,2.0,0.010432665,-0.10505319,0.36211282
Folding of actin by CCT/TriC,0.0004096367,7.0,0.0004096367,-0.26421988,0.030351965
Formation of ATP by chemiosmotic coupling,0.0,1.0,0.0,-0.27072495,0.27347687
Formation of Incision Complex in GG-NER,0.0019086675,36.0,0.0019086675,-0.24041514,-1.1507442
Formation of RNA Pol II elongation complex ,0.002501723,46.0,0.002501723,-0.23099735,-1.5570699
Formation of Senescence-Associated Heterochromatin Foci (SAHF),9.032126e-05,6.0,9.032126e-05,-0.26929066,0.0677444
Formation of TC-NER Pre-Incision Complex,0.011149531,44.0,0.011149531,-0.09366928,-1.3665612
Formation of a pool of free 40S subunits,0.111410975,43.0,0.111410975,1.4984926,-0.07577269
Formation of editosomes by ADAR proteins,1.3357841e-05,2.0,1.3357841e-05,-0.27051285,0.23227169
Formation of selenosugars for excretion,0.0,1.0,0.0,-0.27072495,0.27347687
Formation of the Early Elongation Complex,0.00330528,27.0,0.00330528,-0.21823677,-0.7609957
Formation of the Editosome,0.01123376,7.0,0.01123376,-0.092331715,0.16523774
"Formation of the active cofactor, UDP-glucuronate",1.7317768e-10,2.0,1.7317768e-10,-0.27072495,0.23210524
Formation of the cornified envelope,0.0023120742,54.0,0.0023120742,-0.23400898,-1.890406
"Formation of the ternary complex, and subsequently, the 43S complex",0.04944951,26.0,0.04944951,0.5145383,-0.14459378
Formation of tubulin folding intermediates by CCT/TriC,0.018619623,14.0,0.018619623,0.024956537,-0.03232388
Formation of xylulose-5-phosphate,0.023702411,4.0,0.023702411,0.105671726,0.44473177
Free fatty acid receptors,1.8405286e-05,2.0,1.8405286e-05,-0.27043268,0.23233458
Fructose biosynthesis,0.009954492,3.0,0.009954492,-0.11264663,0.31478244
Fructose catabolism,0.020429185,5.0,0.020429185,0.053692557,0.36257052
Fusion and Uncoating of the Influenza Virion,0.0,1.0,0.0,-0.27072495,0.27347687
G alpha (12/13) signalling events,0.019810125,63.0,0.019810125,0.043861832,-2.044697
G alpha (z) signalling events,0.001433074,23.0,0.001433074,-0.2479676,-0.61884004
G beta:gamma signalling through PI3Kgamma,0.023065938,19.0,0.023065938,0.09556446,-0.18377374
G beta:gamma signalling through PLC beta,0.010025392,17.0,0.010025392,-0.11152072,-0.26353645
G1/S-Specific Transcription,0.015434266,10.0,0.015434266,-0.025627255,0.09346793
G2 Phase,1.5343501e-05,4.0,1.5343501e-05,-0.27048132,0.14955325
G2/M DNA replication checkpoint,7.3444634e-10,2.0,7.3444634e-10,-0.27072495,0.23210524
GAB1 signalosome,3.4052286e-05,8.0,3.4052286e-05,-0.2701842,-0.015699986
GABA A (rho) receptor activation,0.00010115564,3.0,0.00010115564,-0.26911858,0.19199423
GABA A receptor activation,0.000752357,9.0,0.000752357,-0.25877744,-0.048120372
GABA B receptor activation,0.004425532,24.0,0.004425532,-0.20044707,-0.6229208
GABA synthesis,0.0004945396,2.0,0.0004945396,-0.26287162,0.23826799
GLI proteins bind promoters of Hh responsive genes to promote transcription,0.09778755,8.0,0.09778755,1.2821513,1.2024637
GLI3 is processed to GLI3R by the proteasome,0.0038357354,39.0,0.0038357354,-0.20981309,-1.2508446
GP1b-IX-V activation signalling,0.009040644,6.0,0.009040644,-0.12715861,0.17927964
GPVI-mediated activation cascade,0.0010346308,24.0,0.0010346308,-0.25429493,-0.6651768
GRB2 events in EGFR signaling,0.0014986796,5.0,0.0014986796,-0.24692579,0.12666638
GRB2 events in ERBB2 signaling,0.0007771683,10.0,0.0007771683,-0.25838345,-0.0891828
GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.003782744,10.0,0.003782744,-0.21065462,-0.051728554
GRB7 events in ERBB2 signaling,0.00063175516,5.0,0.00063175516,-0.26069263,0.11586314
GTP hydrolysis and joining of the 60S ribosomal subunit,0.036929395,51.0,0.036929395,0.31571758,-1.3349043
Galactose catabolism,0.0028843486,5.0,0.0028843486,-0.22492121,0.14393403
Gamma-carboxylation of protein precursors,0.004772336,5.0,0.004772336,-0.19493978,0.16746135
Gap junction assembly,0.0012785353,10.0,0.0012785353,-0.2504217,-0.08293497
Gap junction degradation,7.0556314e-05,7.0,7.0556314e-05,-0.2696045,0.026126502
Gap-filling DNA repair synthesis and ligation in GG-NER,0.0022498162,19.0,0.0022498162,-0.23499766,-0.4431757
Gap-filling DNA repair synthesis and ligation in TC-NER,2.1415079e-05,50.0,2.1415079e-05,-0.2703849,-1.7534648
Gastrin-CREB signalling pathway via PKC and MAPK,0.034504965,13.0,0.034504965,0.2772174,0.20700431
Generation of second messenger molecules,0.018897345,13.0,0.018897345,0.029366795,0.012508583
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,2.942037e-05,25.0,2.942037e-05,-0.27025777,-0.71907496
Glucagon-type ligand receptors,0.013410557,22.0,0.013410557,-0.05776396,-0.42820993
Glucocorticoid biosynthesis,0.010551335,5.0,0.010551335,-0.10316869,0.23947684
Gluconeogenesis,0.010125913,23.0,0.010125913,-0.10992444,-0.5105134
Glutamate Neurotransmitter Release Cycle,0.041403584,12.0,0.041403584,0.38676816,0.33434364
Glutathione synthesis and recycling,0.00010700105,7.0,0.00010700105,-0.26902577,0.026580662
Glycerophospholipid catabolism,0.0030803466,4.0,0.0030803466,-0.22180875,0.18774807
Glycine degradation,0.0031184945,3.0,0.0031184945,-0.22120295,0.22959507
Glycogen breakdown (glycogenolysis),0.0016400258,15.0,0.0016400258,-0.2446812,-0.28528824
Glycogen storage disease type 0 (liver GYS2),9.3548515e-05,3.0,9.3548515e-05,-0.26923943,0.19189942
Glycogen storage disease type 0 (muscle GYS1),0.007170459,3.0,0.007170459,-0.15685734,0.280089
Glycogen storage disease type II (GAA),0.0043130955,2.0,0.0043130955,-0.20223257,0.28585327
Glycogen storage disease type IV (GBE1),7.3788964e-05,3.0,7.3788964e-05,-0.26955318,0.19165319
Glycogen storage disease type Ia (G6PC),0.0,1.0,0.0,-0.27072495,0.27347687
Glycogen storage disease type Ib (SLC37A4),0.0,1.0,0.0,-0.27072495,0.27347687
Glycogen storage disease type XV (GYG1),0.0033477861,3.0,0.0033477861,-0.21756178,0.2324524
Glycogen synthesis,0.0661886,13.0,0.0661886,0.7803568,0.60183275
Glycoprotein hormones,6.184368e-05,3.0,6.184368e-05,-0.26974288,0.19150434
Glycosphingolipid metabolism,0.00032818818,25.0,0.00032818818,-0.2655133,-0.7153518
Golgi Associated Vesicle Biogenesis,0.006070962,49.0,0.006070962,-0.17431746,-1.6367064
Golgi Cisternae Pericentriolar Stack Reorganization,0.014370984,10.0,0.014370984,-0.042512275,0.08021775
Growth hormone receptor signaling,0.024200732,14.0,0.024200732,0.113585114,0.037225604
HATs acetylate histones,3.0347715e-05,62.0,3.0347715e-05,-0.27024305,-2.2498128
HCN channels,0.008148036,4.0,0.008148036,-0.14133333,0.25089952
HDACs deacetylate histones,0.0006953393,25.0,0.0006953393,-0.25968292,-0.71077657
HDL assembly,0.002067817,4.0,0.002067817,-0.23788781,0.17513035
HDL clearance,0.00051555136,3.0,0.00051555136,-0.26253796,0.19715826
HDL remodeling,7.9698744e-05,5.0,7.9698744e-05,-0.26945934,0.10898363
HDMs demethylate histones,0.00014696334,21.0,0.00014696334,-0.2683912,-0.5521238
HDR through Homologous Recombination (HRR),0.000535162,49.0,0.000535162,-0.26222652,-1.7056911
HDR through MMEJ (alt-NHEJ),3.4343862e-05,9.0,3.4343862e-05,-0.2701796,-0.057067975
HDR through Single Strand Annealing (SSA),0.002669032,30.0,0.002669032,-0.22834048,-0.8930392
HHAT G278V abrogates palmitoylation of Hh-Np,0.0,1.0,0.0,-0.27072495,0.27347687
HS-GAG biosynthesis,0.109499,18.0,0.109499,1.4681302,0.9346911
HS-GAG degradation,0.038430672,11.0,0.038430672,0.339558,0.33866805
HSF1 activation,0.00042204498,12.0,0.00042204498,-0.26402283,-0.17635138
HSP90 chaperone cycle for steroid hormone receptors (SHR),3.9259985e-06,15.0,3.9259985e-06,-0.2706626,-0.30567664
Heme biosynthesis,0.00873842,7.0,0.00873842,-0.13195796,0.13414183
Heme degradation,0.0021874001,3.0,0.0021874001,-0.23598883,0.21799213
Hereditary fructose intolerance,0.0,1.0,0.0,-0.27072495,0.27347687
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD,0.02154687,37.0,0.02154687,0.071441524,-0.94739264
Histidine catabolism,0.008052551,5.0,0.008052551,-0.14284964,0.20833804
Hormone ligand-binding receptors,0.00052037084,6.0,0.00052037084,-0.26246142,0.0731035
HuR (ELAVL1) binds and stabilizes mRNA,0.0014123211,8.0,0.0014123211,-0.24829717,0.0014754276
Hyaluronan biosynthesis and export,0.0019836458,3.0,0.0019836458,-0.23922446,0.21545303
Hyaluronan uptake and degradation,0.119510606,10.0,0.119510606,1.6271156,1.3904244
Hydrolysis of LPC,0.01584303,7.0,0.01584303,-0.019136041,0.22267655
Hydrolysis of LPE,0.009742579,2.0,0.009742579,-0.11601181,0.35351324
Hydroxycarboxylic acid-binding receptors,0.0,1.0,0.0,-0.27072495,0.27347687
Hypusine synthesis from eIF5A-lysine,0.0039207563,5.0,0.0039207563,-0.20846295,0.15684931
IKBKB deficiency causes SCID,6.359923e-06,2.0,6.359923e-06,-0.27062398,0.23218447
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR),5.317537e-07,3.0,5.317537e-07,-0.27071655,0.19074029
IL-6-type cytokine receptor ligand interactions,0.032233812,11.0,0.032233812,0.24115124,0.26144534
IP3 and IP4 transport between cytosol and nucleus,0.0,1.0,0.0,-0.27072495,0.27347687
IP6 and IP7 transport between cytosol and nucleus,0.0,1.0,0.0,-0.27072495,0.27347687
IPs transport between ER lumen and cytosol,0.0,1.0,0.0,-0.27072495,0.27347687
IPs transport between ER lumen and nucleus,0.0,1.0,0.0,-0.27072495,0.27347687
IPs transport between cytosol and ER lumen,0.0,1.0,0.0,-0.27072495,0.27347687
IPs transport between nucleus and ER lumen,0.0,1.0,0.0,-0.27072495,0.27347687
IPs transport between nucleus and cytosol,0.0,1.0,0.0,-0.27072495,0.27347687
IRAK4 deficiency (TLR2/4),1.8209552e-07,5.0,1.8209552e-07,-0.27072206,0.10799273
IRAK4 deficiency (TLR5),3.0565516e-05,4.0,3.0565516e-05,-0.27023956,0.14974296
IRF3 mediated activation of type 1 IFN,0.002790985,3.0,0.002790985,-0.22640385,0.22551377
IRF3-mediated induction of type I IFN,0.00091871514,3.0,0.00091871514,-0.2561357,0.2021823
IRS activation,0.03490846,4.0,0.03490846,0.2836249,0.5843769
IRS-mediated signalling,0.017013287,34.0,0.017013287,-0.0005522398,-0.87977344
ISG15 antiviral mechanism,0.094332896,56.0,0.094332896,1.227291,-0.8264237
IkBA variant leads to EDA-ID,5.057838e-05,7.0,5.057838e-05,-0.26992178,0.025877545
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.023987252,31.0,0.023987252,0.11019503,-0.6687519
Import of palmitoyl-CoA into the mitochondrial matrix,0.025480758,9.0,0.025480758,0.13391206,0.26003474
Inactivation of APC/C via direct inhibition of the APC/C complex,0.020250855,15.0,0.020250855,0.050860666,-0.053367738
Inactivation of CDC42 and RAC1,0.0038989454,7.0,0.0038989454,-0.20880932,0.0738343
Influenza Viral RNA Transcription and Replication,0.05970544,56.0,0.05970544,0.67740345,-1.2579368
Influenza Virus Induced Apoptosis,0.0,1.0,0.0,-0.27072495,0.27347687
Inhibition of Signaling by Overexpressed EGFR,0.0015966694,2.0,0.0015966694,-0.24536969,0.25200227
Inhibition of TSC complex formation by PKB,9.4139534e-05,4.0,9.4139534e-05,-0.26923,0.15053521
InlA-mediated entry of Listeria monocytogenes into host cells,0.025102166,8.0,0.025102166,0.12789999,0.29668853
InlB-mediated entry of Listeria monocytogenes into host cell,0.0066235797,12.0,0.0066235797,-0.16554186,-0.09907044
Inositol transporters,0.03175327,4.0,0.03175327,0.23352021,0.54505825
Insulin effects increased synthesis of Xylulose-5-Phosphate,0.00059195387,2.0,0.00059195387,-0.26132467,0.23948194
Insulin processing,0.02818116,20.0,0.02818116,0.17679471,-0.16140155
Insulin receptor recycling,0.0706618,17.0,0.0706618,0.8513916,0.49208945
Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA,0.0009605299,7.0,0.0009605299,-0.25547165,0.037216987
Integrin cell surface interactions,0.096776694,27.0,0.096776694,1.2660987,0.40380648
Interaction With Cumulus Cells,0.0,1.0,0.0,-0.27072495,0.27347687
Interaction With The Zona Pellucida,0.0005623185,6.0,0.0005623185,-0.2617953,0.07362622
Interaction between L1 and Ankyrins,0.003349972,9.0,0.003349972,-0.21752708,-0.015749982
Interaction between PHLDA1 and AURKA,0.0,1.0,0.0,-0.27072495,0.27347687
Interactions of Rev with host cellular proteins,0.00045145824,29.0,0.00045145824,-0.26355577,-0.8793021
Interactions of Tat with host cellular proteins,0.0005402042,2.0,0.0005402042,-0.26214647,0.23883705
Interactions of Vpr with host cellular proteins,0.0027266634,28.0,0.0027266634,-0.22742528,-0.8095778
Interconversion of 2-oxoglutarate and 2-hydroxyglutarate,0.00011814163,4.0,0.00011814163,-0.26884887,0.1508343
Interconversion of nucleotide di- and triphosphates,0.0014627189,15.0,0.0014627189,-0.24749684,-0.2874978
Interconversion of polyamines,0.0,1.0,0.0,-0.27072495,0.27347687
Interleukin receptor SHC signaling,0.033328995,17.0,0.033328995,0.25854287,0.026863458
Interleukin-1 processing,0.003019541,3.0,0.003019541,-0.22277434,0.22836195
Interleukin-10 signaling,0.004486451,7.0,0.004486451,-0.19947967,0.08115555
Interleukin-12 signaling,0.0017494533,23.0,0.0017494533,-0.24294347,-0.61489743
Interleukin-15 signaling,0.009720974,10.0,0.009720974,-0.11635492,0.02227123
Interleukin-18 signaling,0.0028504988,2.0,0.0028504988,-0.22545876,0.267627
Interleukin-2 signaling,0.0040602614,10.0,0.0040602614,-0.20624761,-0.048270244
Interleukin-20 family signaling,0.017790124,16.0,0.017790124,0.011784005,-0.12540396
Interleukin-21 signaling,0.0012930757,8.0,0.0012930757,-0.2501908,-1.0543024e-05
Interleukin-23 signaling,0.0005898286,4.0,0.0005898286,-0.2613584,0.15671228
Interleukin-27 signaling,0.0006931257,9.0,0.0006931257,-0.25971806,-0.048858497
Interleukin-33 signaling,0.0097366,3.0,0.0097366,-0.11610676,0.31206715
Interleukin-35 Signalling,0.005261168,8.0,0.005261168,-0.18717709,0.049438175
Interleukin-36 pathway,0.040810946,4.0,0.040810946,0.377357,0.65793127
Interleukin-37 signaling,0.035422593,15.0,0.035422593,0.2917894,0.13569622
Interleukin-38 signaling,0.004392419,2.0,0.004392419,-0.2009729,0.28684178
Interleukin-4 and Interleukin-13 signaling,0.13628817,54.0,0.13628817,1.8935449,-0.22085121
Interleukin-6 signaling,0.0018290931,8.0,0.0018290931,-0.24167877,0.006669077
Interleukin-7 signaling,0.02009905,18.0,0.02009905,0.04844998,-0.17937429
Interleukin-9 signaling,0.0013474298,8.0,0.0013474298,-0.24932764,0.0006667862
Intestinal hexose absorption,1.6740545e-05,2.0,1.6740545e-05,-0.27045912,0.23231386
Intestinal infectious diseases,0.0045447615,2.0,0.0045447615,-0.1985537,0.28874016
Intestinal lipid absorption,6.470873e-05,2.0,6.470873e-05,-0.2696974,0.2329116
Intestinal saccharidase deficiencies,0.0,1.0,0.0,-0.27072495,0.27347687
Intra-Golgi traffic,0.05335145,33.0,0.05335145,0.5765014,-0.38557056
Intracellular oxygen transport,8.744844e-05,2.0,8.744844e-05,-0.26933625,0.233195
Intraflagellar transport,0.0036844765,28.0,0.0036844765,-0.21221511,-0.797642
Intrinsic Pathway of Fibrin Clot Formation,0.008653826,7.0,0.008653826,-0.13330133,0.13308766
Invadopodia formation,0.0063317656,4.0,0.0063317656,-0.17017588,0.22826591
Ion homeostasis,0.0005241678,20.0,0.0005241678,-0.26240113,-0.5060516
Ion influx/efflux at host-pathogen interface,0.005392606,3.0,0.005392606,-0.18508984,0.25793406
Ion transport by P-type ATPases,0.17093435,28.0,0.17093435,2.4437299,1.286557
Ionotropic activity of kainate receptors,0.12807208,6.0,0.12807208,1.7630727,1.6626004
Josephin domain DUBs,0.10574673,7.0,0.10574673,1.4085438,1.3430194
KSRP (KHSRP) binds and destabilizes mRNA,0.0076227677,13.0,0.0076227677,-0.14967465,-0.12799056
Keratan sulfate biosynthesis,0.11000166,15.0,0.11000166,1.4761126,1.0650698
Keratan sulfate degradation,0.14428195,6.0,0.14428195,2.020487,1.8646011
Kinesins,0.008584502,19.0,0.008584502,-0.1344022,-0.36423546
L13a-mediated translational silencing of Ceruloplasmin expression,0.003956442,51.0,0.003956442,-0.20789626,-1.7457997
LDL clearance,0.0018384599,12.0,0.0018384599,-0.24153005,-0.15870062
LDL remodeling,0.0,1.0,0.0,-0.27072495,0.27347687
LGI-ADAM interactions,9.592122e-06,8.0,9.592122e-06,-0.27057263,-0.016004803
LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production,0.0022498013,5.0,0.0022498013,-0.23499788,0.13602656
Lactose synthesis,0.028661821,4.0,0.028661821,0.18442766,0.50653386
Laminin interactions,0.06687003,13.0,0.06687003,0.79117787,0.6103244
Late Phase of HIV Life Cycle,0.0007073642,102.0,0.0007073642,-0.25949195,-3.89624
Ligand-receptor interactions,6.808251e-05,4.0,6.808251e-05,-0.26964378,0.1502105
Linoleic acid (LA) metabolism,0.0020574648,4.0,0.0020574648,-0.23805222,0.17500134
Lipid particle organization,0.0034041714,5.0,0.0034041714,-0.21666639,0.15041184
Localization of the PINCH-ILK-PARVIN complex to focal adhesions,0.0,1.0,0.0,-0.27072495,0.27347687
Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling,0.010086862,6.0,0.010086862,-0.11054457,0.19231719
Lysine catabolism,0.0063460837,9.0,0.0063460837,-0.1699485,0.021586336
Lysosomal oligosaccharide catabolism,0.00047670174,5.0,0.00047670174,-0.2631549,0.1139309
Lysosome Vesicle Biogenesis,0.00044260974,28.0,0.00044260974,-0.26369628,-0.83804077
Lysosphingolipid and LPA receptors,0.0062241284,6.0,0.0062241284,-0.17188518,0.14418139
MAP kinase activation,0.0019791804,46.0,0.0019791804,-0.23929538,-1.5635815
MAP2K and MAPK activation,0.020946816,29.0,0.020946816,0.061912593,-0.6238974
MAPK1 (ERK2) activation,0.00019529577,3.0,0.00019529577,-0.26762363,0.19316737
MAPK3 (ERK1) activation,9.950232e-05,3.0,9.950232e-05,-0.26914486,0.19197363
MAPK6/MAPK4 signaling,0.0029996394,61.0,0.0029996394,-0.2230904,-2.1714392
MASTL Facilitates Mitotic Progression,0.00536,8.0,0.00536,-0.18560763,0.050669782
MET Receptor Activation,0.0077585992,3.0,0.0077585992,-0.14751764,0.28741813
MET activates PI3K/AKT signaling,0.00012826682,5.0,0.00012826682,-0.26868805,0.109588884
MET activates PTK2 signaling,0.0073194457,4.0,0.0073194457,-0.15449142,0.24057397
MET activates PTPN11,9.9212275e-06,4.0,9.9212275e-06,-0.27056742,0.14948569
MET activates RAP1 and RAC1,0.005565812,10.0,0.005565812,-0.18233931,-0.029508691
MET activates RAS signaling,0.008494783,8.0,0.008494783,-0.13582695,0.08973416
MET activates STAT3,0.0022078888,3.0,0.0022078888,-0.23566347,0.21824746
MET interacts with TNS proteins,0.013981006,2.0,0.013981006,-0.04870517,0.4063308
MET receptor recycling,0.0012593098,6.0,0.0012593098,-0.250727,0.082311854
MGMT-mediated DNA damage reversal,0.0013652479,2.0,0.0013652479,-0.24904469,0.2491184
MHC class II antigen presentation,0.00039562417,66.0,0.00039562417,-0.2644424,-2.4107473
MPS I - Hurler syndrome,0.0,1.0,0.0,-0.27072495,0.27347687
MPS II - Hunter syndrome,0.0,1.0,0.0,-0.27072495,0.27347687
MPS IIIA - Sanfilippo syndrome A,0.0,1.0,0.0,-0.27072495,0.27347687
MPS IIIB - Sanfilippo syndrome B,0.0,1.0,0.0,-0.27072495,0.27347687
MPS IIIC - Sanfilippo syndrome C,0.0,1.0,0.0,-0.27072495,0.27347687
MPS IIID - Sanfilippo syndrome D,0.0,1.0,0.0,-0.27072495,0.27347687
MPS IV - Morquio syndrome A,0.0,1.0,0.0,-0.27072495,0.27347687
MPS IV - Morquio syndrome B,0.0,1.0,0.0,-0.27072495,0.27347687
MPS IX - Natowicz syndrome,0.0,1.0,0.0,-0.27072495,0.27347687
MPS VI - Maroteaux-Lamy syndrome,0.0,1.0,0.0,-0.27072495,0.27347687
MPS VII - Sly syndrome,0.0,1.0,0.0,-0.27072495,0.27347687
MTF1 activates gene expression,1.96732e-05,4.0,1.96732e-05,-0.27041256,0.14960723
Macroautophagy,0.010983614,44.0,0.010983614,-0.09630406,-1.3686287
Major pathway of rRNA processing in the nucleolus and cytosol,0.0035485008,96.0,0.0035485008,-0.21437441,-3.6126053
Meiotic recombination,0.017019292,16.0,0.017019292,-0.00045687714,-0.13500974
Meiotic synapsis,0.00093987817,23.0,0.00093987817,-0.25579962,-0.624986
Melanin biosynthesis,0.00057577033,3.0,0.00057577033,-0.2615817,0.19790867
Metabolism of Angiotensinogen to Angiotensins,0.0081064515,5.0,0.0081064515,-0.14199369,0.2090097
Metabolism of folate and pterines,0.032991327,11.0,0.032991327,0.25318065,0.27088517
Metabolism of ingested H2SeO4 and H2SeO3 into H2Se,6.460776e-05,4.0,6.460776e-05,-0.26969898,0.15016718
Metabolism of ingested MeSeO2H into MeSeH,0.00022472885,2.0,0.00022472885,-0.26715627,0.2349057
"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.0017425884,7.0,0.0017425884,-0.24305248,0.046962667
Metabolism of serotonin,9.333941e-07,2.0,9.333941e-07,-0.27071014,0.23211688
Metabolism of vitamin K,0.00588384,3.0,0.00588384,-0.177289,0.26405567
Metal sequestration by antimicrobial proteins,1.2564516e-06,2.0,1.2564516e-06,-0.270705,0.23212092
Metalloprotease DUBs,0.13710134,16.0,0.13710134,1.9064583,1.3614032
Metallothioneins bind metals,4.6682867e-06,3.0,4.6682867e-06,-0.27065083,0.19079185
Methionine salvage pathway,0.008133138,6.0,0.008133138,-0.14156991,0.16797067
Methylation,0.0020402744,10.0,0.0020402744,-0.2383252,-0.07344248
Methylation of MeSeH for excretion,0.015931219,2.0,0.015931219,-0.017735595,0.43063354
MicroRNA (miRNA) biogenesis,0.0006520257,16.0,0.0006520257,-0.26037073,-0.33897188
Mineralocorticoid biosynthesis,0.004196664,3.0,0.004196664,-0.2040815,0.24303077
Miscellaneous substrates,0.0006855771,6.0,0.0006855771,-0.25983796,0.07516224
Miscellaneous transport and binding events,0.00022757956,17.0,0.00022757956,-0.26711097,-0.38563275
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta),0.0010771819,10.0,0.0010771819,-0.2536192,-0.08544414
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha),0.0005010544,11.0,0.0005010544,-0.26276815,-0.1339952
Misspliced GSK3beta mutants stabilize beta-catenin,0.005837503,12.0,0.005837503,-0.17802483,-0.10886619
Misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling,0.000844187,4.0,0.000844187,-0.2573192,0.15988198
Mitochondrial ABC transporters,0.0022119137,5.0,0.0022119137,-0.23559956,0.13555442
Mitochondrial protein import,0.00032318055,38.0,0.00032318055,-0.26559284,-1.2532451
Mitochondrial tRNA aminoacylation,0.07716809,14.0,0.07716809,0.9547122,0.69728297
Mitochondrial transcription initiation,8.327726e-05,3.0,8.327726e-05,-0.2694025,0.19177143
Mitochondrial transcription termination,1.3803315e-05,2.0,1.3803315e-05,-0.27050576,0.23227726
Mitochondrial translation elongation,0.008384313,51.0,0.008384313,-0.13758121,-1.6906214
Mitochondrial translation initiation,0.18437716,51.0,0.18437716,2.6572032,0.5025291
Mitochondrial translation termination,0.0093992865,51.0,0.0093992865,-0.12146334,-1.6779733
Mitotic Anaphase,0.0070195086,110.0,6.381371e-05,-0.26971158,-4.1485534
Mitotic Metaphase/Anaphase Transition,2.7655356e-05,2.0,2.7655356e-05,-0.27028582,0.23244986
Molecules associated with elastic fibres,0.008831245,15.0,0.008831245,-0.1304839,-0.19567423
Molybdenum cofactor biosynthesis,0.014490041,6.0,0.014490041,-0.040621646,0.24718776
Mtb iron assimilation by chelation,0.0,1.0,0.0,-0.27072495,0.27347687
Multifunctional anion exchangers,0.006958749,5.0,0.006958749,-0.16021933,0.19470753
MyD88 deficiency (TLR2/4),2.1953894e-05,4.0,2.1953894e-05,-0.27037635,0.14963564
MyD88 deficiency (TLR5),7.932266e-06,2.0,7.932266e-06,-0.27059898,0.23220411
MyD88 dependent cascade initiated on endosome,0.0017081536,56.0,0.0017081536,-0.24359931,-1.9806751
MyD88-independent TLR4 cascade ,0.017908933,64.0,0.017908933,0.0136707015,-2.1097603
Myoclonic epilepsy of Lafora,0.00049426,9.0,0.00049426,-0.26287606,-0.051336687
N-glycan antennae elongation in the medial/trans-Golgi,0.008137381,17.0,0.008137381,-0.14150253,-0.28706408
N-glycan trimming and elongation in the cis-Golgi,0.0036466655,4.0,0.0036466655,-0.21281555,0.19480531
NADE modulates death signalling,0.0016963403,5.0,0.0016963403,-0.2437869,0.12912956
NADPH regeneration,0.0048230016,2.0,0.0048230016,-0.19413522,0.2922075
NCAM1 interactions,0.023333456,23.0,0.023333456,0.09981269,-0.34592646
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10,0.0034663808,10.0,0.0034663808,-0.21567848,-0.05567093
NF-kB is activated and signals survival,0.020543633,11.0,0.020543633,0.05551001,0.11576714
NFG and proNGF binds to p75NTR,0.0036878102,2.0,0.0036878102,-0.21216217,0.27806124
NGF processing,0.0015901258,3.0,0.0015901258,-0.2454736,0.21054916
NIK-->noncanonical NF-kB signaling,0.0031899905,38.0,0.0031899905,-0.22006759,-1.2175201
NOD1/2 Signaling Pathway,0.08617596,25.0,0.08617596,1.097758,0.3544478
NOSIP mediated eNOS trafficking,0.0,1.0,0.0,-0.27072495,0.27347687
NOSTRIN mediated eNOS trafficking,0.014369735,4.0,0.014369735,-0.042532124,0.3284318
NOTCH1 Intracellular Domain Regulates Transcription,0.005727236,32.0,0.005727236,-0.17977588,-0.9376723
NOTCH2 Activation and Transmission of Signal to the Nucleus,0.056116085,16.0,0.056116085,0.6204041,0.3521984
NOTCH2 intracellular domain regulates transcription,0.0017634694,8.0,0.0017634694,-0.24272089,0.005851297
NOTCH3 Intracellular Domain Regulates Transcription,0.00010412345,17.0,0.00010412345,-0.26907146,-0.38717124
NOTCH4 Activation and Transmission of Signal to the Nucleus,0.0007658507,8.0,0.0007658507,-0.2585632,-0.0065806243
NOTCH4 Intracellular Domain Regulates Transcription,0.00021047417,10.0,0.00021047417,-0.26738262,-0.096244715
NR1D1 (REV-ERBA) represses gene expression,0.027782597,3.0,0.027782597,0.17046548,0.5369489
NRAGE signals death through JNK,0.013667243,43.0,0.013667243,-0.053687766,-1.2938149
NRIF signals cell death from the nucleus,0.000618326,13.0,0.000618326,-0.2609059,-0.21527706
NS1 Mediated Effects on Host Pathways,0.051359236,30.0,0.051359236,0.54486495,-0.28628197
NTF3 activates NTRK2 (TRKB) signaling,7.5384196e-05,3.0,7.5384196e-05,-0.26952785,0.19167309
NTF3 activates NTRK3 signaling,0.0003236738,3.0,0.0003236738,-0.265585,0.19476716
NTF4 activates NTRK2 (TRKB) signaling,0.000120517616,2.0,0.000120517616,-0.26881114,0.23360707
NTRK3 as a dependence receptor,0.0012148832,4.0,0.0012148832,-0.2514325,0.16450143
Na+/Cl- dependent neurotransmitter transporters,0.056485664,6.0,0.056485664,0.6262731,0.77052
Nectin/Necl  trans heterodimerization,0.00016326562,2.0,0.00016326562,-0.26813227,0.2341398
Neddylation,0.021648148,162.0,0.00013363054,-0.2686029,-6.117581
Negative regulation of FGFR1 signaling,0.0017002947,26.0,0.0017002947,-0.24372411,-0.7396248
Negative regulation of FGFR2 signaling,0.006655421,25.0,0.006655421,-0.1650362,-0.6365045
Negative regulation of FGFR3 signaling,0.09842119,23.0,0.09842119,1.2922136,0.58978593
Negative regulation of FGFR4 signaling,0.001738335,26.0,0.001738335,-0.24312003,-0.73915076
Negative regulation of MAPK pathway,0.05987787,28.0,0.05987787,0.6801416,-0.09738301
Negative regulation of MET activity,0.080778666,17.0,0.080778666,1.0120485,0.6181617
Negative regulation of NOTCH4 signaling,0.0021446068,36.0,0.0021446068,-0.2366684,-1.147804
Negative regulation of TCF-dependent signaling by DVL-interacting proteins,0.0019734523,5.0,0.0019734523,-0.23938635,0.13258281
Negative regulation of TCF-dependent signaling by WNT ligand antagonists,0.0005707002,9.0,0.0005707002,-0.2616622,-0.05038412
Negative regulation of activity of TFAP2 (AP-2) family transcription factors,7.2359515e-05,9.0,7.2359515e-05,-0.2695759,-0.05659423
Negative regulators of DDX58/IFIH1 signaling,0.0044182586,28.0,0.0044182586,-0.20056257,-0.78849787
Nephrin family interactions,0.00017349346,15.0,0.00017349346,-0.26796985,-0.30356354
Netrin mediated repulsion signals,0.0008510874,6.0,0.0008510874,-0.2572096,0.07722476
Neurexins and neuroligins,0.0012128642,34.0,0.0012128642,-0.25146458,-1.0766718
Neurofascin interactions,2.5913187e-07,5.0,2.5913187e-07,-0.27072084,0.10799369
Neurophilin interactions with VEGF and VEGFR,0.00027338372,2.0,0.00027338372,-0.2663836,0.23551203
Neutrophil degranulation,0.0006561984,255.0,2.573327e-06,-0.2706841,-10.226732
Nicotinamide salvaging,0.001980133,11.0,0.001980133,-0.23928025,-0.115563534
NoRC negatively regulates rRNA expression,0.0023977344,35.0,0.0023977344,-0.2326487,-1.103278
Noncanonical activation of NOTCH3,2.9252642e-06,6.0,2.9252642e-06,-0.27067852,0.06665529
Nonhomologous End-Joining (NHEJ),0.0002495999,27.0,0.0002495999,-0.2667613,-0.79907435
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC),0.006788712,54.0,0.006788712,-0.16291954,-1.83462
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC),0.0006643168,38.0,0.0006643168,-0.26017556,-1.248994
Norepinephrine Neurotransmitter Release Cycle,0.058374427,8.0,0.058374427,0.65626687,0.7113137
Notch-HLH transcription pathway,0.00019719775,12.0,0.00019719775,-0.26759344,-0.17915334
NrCAM interactions,0.00017670605,5.0,0.00017670605,-0.26791885,0.1101925
Nuclear Envelope Breakdown,0.014831299,35.0,0.014831299,-0.035202432,-0.94833606
Nuclear Events (kinase and transcription factor activation),0.006844252,19.0,0.006844252,-0.16203755,-0.38592172
Nuclear Receptor transcription pathway,0.024090301,33.0,0.024090301,0.111831464,-0.750211
Nuclear signaling by ERBB4,0.003024126,18.0,0.003024126,-0.22270155,-0.39215496
Nucleotide-like (purinergic) receptors,0.0016918877,5.0,0.0016918877,-0.2438576,0.12907407
O-glycosylation of TSR domain-containing proteins,0.0184368,12.0,0.0184368,0.0220533,0.04814107
Olfactory Signaling Pathway,0.0011014162,219.0,5.029298e-06,-0.2706451,-8.731807
Oncogene Induced Senescence,0.102651075,24.0,0.102651075,1.3593845,0.6011254
Opioid Signalling,0.03533207,51.0,0.03533207,0.29035187,-1.3548096
Opsins,0.002004249,8.0,0.002004249,-0.2388973,0.008851799
Orc1 removal from chromatin,0.00035315825,49.0,0.00035315825,-0.26511678,-1.7079592
Organic anion transport,2.2841723e-05,3.0,2.2841723e-05,-0.27036223,0.19101831
Organic anion transporters,0.010414888,4.0,0.010414888,-0.10533549,0.2791481
Organic cation transport,0.0005819272,2.0,0.0005819272,-0.2614839,0.23935698
Other interleukin signaling,0.061183926,18.0,0.061183926,0.70088196,0.33260852
Other semaphorin interactions,0.05562402,10.0,0.05562402,0.6125901,0.59429604
Ovarian tumor domain proteases,0.0031471818,28.0,0.0031471818,-0.2207474,-0.8043375
Oxidative Stress Induced Senescence,0.02068797,42.0,0.02068797,0.05780209,-1.1649538
Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha,0.0012328724,3.0,0.0012328724,-0.25114682,0.2060972
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.058276128,40.0,0.058276128,0.6547058,-0.6138025
PAOs oxidise polyamines to amines,0.0,1.0,0.0,-0.27072495,0.27347687
PCNA-Dependent Long Patch Base Excision Repair,0.24204254,15.0,0.24204254,3.572935,2.710509
PD-1 signaling,0.0059568672,8.0,0.0059568672,-0.1761293,0.058107696
PECAM1 interactions,0.0006962382,10.0,0.0006962382,-0.25966865,-0.09019132
PI and PC transport between ER and Golgi membranes,0.0061810114,3.0,0.0061810114,-0.17256989,0.26775888
PI3K events in ERBB2 signaling,4.0277588e-05,11.0,4.0277588e-05,-0.27008533,-0.13973723
PI3K events in ERBB4 signaling,0.00023865081,7.0,0.00023865081,-0.26693517,0.028221227
PI3K/AKT activation,0.0043230844,8.0,0.0043230844,-0.20207396,0.037748158
"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",0.057498634,62.0,0.057498634,0.6423592,-1.5336667
PIPs transport between Golgi and plasma membranes,0.0,1.0,0.0,-0.27072495,0.27347687
PIPs transport between early and late endosome membranes,0.0,1.0,0.0,-0.27072495,0.27347687
PIPs transport between early endosome and Golgi membranes,0.0,1.0,0.0,-0.27072495,0.27347687
PIPs transport between late endosome and Golgi membranes,0.0,1.0,0.0,-0.27072495,0.27347687
PIPs transport between plasma and early endosome membranes,0.0,1.0,0.0,-0.27072495,0.27347687
PIWI-interacting RNA (piRNA) biogenesis,0.0034664208,17.0,0.0034664208,-0.21567786,-0.34527165
PKA activation in glucagon signalling,0.0066054766,9.0,0.0066054766,-0.16582933,0.024818774
PKA-mediated phosphorylation of key metabolic factors,0.00040024804,2.0,0.00040024804,-0.26436898,0.23709297
PKMTs methylate histone lysines,0.0010015937,35.0,0.0010015937,-0.25481954,-1.1206762
PLC-gamma1 signalling,0.0018070805,3.0,0.0018070805,-0.24202834,0.21325277
PLCG1 events in ERBB2 signaling,0.0006498121,4.0,0.0006498121,-0.2604059,0.15745977
POLB-Dependent Long Patch Base Excision Repair,0.030232606,6.0,0.030232606,0.2093719,0.44336513
"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",0.0001564768,9.0,0.0001564768,-0.2682401,-0.055546004
"POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation",0.011850609,7.0,0.011850609,-0.08253609,0.17292467
PP2A-mediated dephosphorylation of key metabolic factors,0.0074056764,5.0,0.0074056764,-0.15312208,0.20027693
PPARA activates gene expression,0.00043174735,28.0,0.00043174735,-0.26386875,-0.83817613
PRC2 methylates histones and DNA,0.0005832837,13.0,0.0005832837,-0.26146236,-0.21571374
PTEN Loss of Function in Cancer,0.0,1.0,0.0,-0.27072495,0.27347687
PTK6 Activates STAT3,4.44334e-05,3.0,4.44334e-05,-0.27001935,0.19128737
PTK6 Down-Regulation,0.0005303967,3.0,0.0005303967,-0.2623022,0.19734326
PTK6 Expression,0.0009057155,5.0,0.0009057155,-0.2563421,0.11927711
PTK6 Regulates Cell Cycle,0.00022368247,7.0,0.00022368247,-0.26717284,0.028034702
PTK6 Regulates Proteins Involved in RNA Processing,0.00027378238,5.0,0.00027378238,-0.26637727,0.111402236
"PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases",0.00028772344,12.0,0.00028772344,-0.2661559,-0.17802528
PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1,0.00036653044,9.0,0.00036653044,-0.2649044,-0.05292839
PTK6 promotes HIF1A stabilization,8.293592e-05,4.0,8.293592e-05,-0.26940793,0.15039557
Packaging Of Telomere Ends,0.089212,7.0,0.089212,1.1459707,1.1369705
Paradoxical activation of RAF signaling by kinase inactive BRAF,0.041018523,28.0,0.041018523,0.38065335,-0.33240047
Passive transport by Aquaporins,0.00036278748,6.0,0.00036278748,-0.26496387,0.071139775
Peptide chain elongation,0.02697788,34.0,0.02697788,0.1576865,-0.7555988
Peptide ligand-binding receptors,0.00809266,66.0,0.00809266,-0.1422127,-2.3148298
Phase 0 - rapid depolarisation,0.0021314078,18.0,0.0021314078,-0.236878,-0.40327963
Phase 1 - inactivation of fast Na+ channels,0.00036109207,7.0,0.00036109207,-0.26499078,0.029747037
Phase 2 - plateau phase,2.2055927e-05,21.0,2.2055927e-05,-0.27037472,-0.5536803
Phase 3 - rapid repolarisation,2.9175445e-07,8.0,2.9175445e-07,-0.27072033,-0.016120682
Phase 4 - resting membrane potential,0.00019870019,9.0,0.00019870019,-0.2675696,-0.05501984
Phenylalanine and tyrosine catabolism,0.0021753123,5.0,0.0021753123,-0.23618078,0.13509831
Phenylketonuria,0.0,1.0,0.0,-0.27072495,0.27347687
Phosphate bond hydrolysis by NTPDase proteins,1.5739459e-05,7.0,1.5739459e-05,-0.27047503,0.025443394
Phosphate bond hydrolysis by NUDT proteins,0.0029068736,6.0,0.0029068736,-0.22456351,0.10284312
Phosphorylation of CD3 and TCR zeta chains,0.016171494,6.0,0.016171494,-0.013919993,0.26814136
Physiological factors,0.0001414053,5.0,0.0001414053,-0.26847944,0.109752595
Pink/Parkin Mediated Mitophagy,0.0004736738,16.0,0.0004736738,-0.26320297,-0.34119442
Plasmalogen biosynthesis,0.09354678,3.0,0.09354678,1.2148074,1.356475
Platelet Adhesion to exposed collagen,0.00087311957,8.0,0.00087311957,-0.25685972,-0.0052438676
Platelet degranulation ,0.025351577,69.0,0.025351577,0.13186064,-2.2238712
Platelet sensitization by LDL,0.013557383,11.0,0.013557383,-0.05543235,0.028707374
Polo-like kinase mediated events,1.4462356e-06,8.0,1.4462356e-06,-0.270702,-0.016106315
Polymerase switching,1.1752414e-05,11.0,1.1752414e-05,-0.27053833,-0.14009269
Post NMDA receptor activation events,0.012638152,22.0,0.012638152,-0.07002983,-0.43783534
Post-chaperonin tubulin folding pathway,0.007549192,10.0,0.007549192,-0.15084304,-0.004792623
Post-transcriptional silencing by small RNAs,0.0006853762,7.0,0.0006853762,-0.2598411,0.033788126
Post-translational protein phosphorylation,0.3536542,61.0,0.3536542,5.34534,2.198274
Potassium transport channels,0.00017263836,3.0,0.00017263836,-0.26798344,0.19288503
Pre-NOTCH Processing in Golgi,0.00027807557,7.0,0.00027807557,-0.26630908,0.028712522
Pre-NOTCH Processing in the Endoplasmic Reticulum,0.0038944646,6.0,0.0038944646,-0.20888047,0.11515007
Pre-NOTCH Transcription and Translation,0.006397791,29.0,0.006397791,-0.16912739,-0.8052013
Prefoldin mediated transfer of substrate  to CCT/TriC,0.0053861705,15.0,0.0053861705,-0.18519203,-0.23860534
Pregnenolone biosynthesis,0.009002122,8.0,0.009002122,-0.12777035,0.09605641
Presynaptic depolarization and calcium channel opening,0.05408821,9.0,0.05408821,0.5882012,0.61652905
Presynaptic function of Kainate receptors,0.05139869,17.0,0.05139869,0.54549146,0.25204057
Processing of DNA double-strand break ends,0.0003472878,50.0,0.0003472878,-0.26521,-1.749404
Processing of Intronless Pre-mRNAs,8.778156e-05,15.0,8.778156e-05,-0.269331,-0.30463168
Processing of SMDT1,0.009885486,9.0,0.009885486,-0.11374244,0.06569291
Processive synthesis on the lagging strand,0.0003215645,11.0,0.0003215645,-0.26561847,-0.13623194
Prolactin receptor signaling,0.0006658421,10.0,0.0006658421,-0.26015133,-0.0905701
Proline catabolism,6.341431e-05,2.0,6.341431e-05,-0.26971796,0.23289548
Propionyl-CoA catabolism,0.10905705,5.0,0.10905705,1.461112,1.4670144
Prostacyclin signalling through prostacyclin receptor,0.001593311,15.0,0.001593311,-0.24542302,-0.28587037
Protein methylation,2.312733e-05,9.0,2.312733e-05,-0.2703577,-0.05720775
Protein repair,0.011421887,4.0,0.011421887,-0.08934424,0.2916969
Proton-coupled monocarboxylate transport,0.015772734,3.0,0.015772734,-0.020252353,0.38728696
Proton-coupled neutral amino acid transporters,1.8081588e-05,2.0,1.8081588e-05,-0.27043784,0.23233056
Proton/oligopeptide cotransporters,0.00018764305,2.0,0.00018764305,-0.26774517,0.23444356
Purine ribonucleoside monophosphate biosynthesis,9.79549e-05,8.0,9.79549e-05,-0.26916945,-0.014903666
Purine salvage,0.00092996785,10.0,0.00092996785,-0.25595698,-0.08727865
Pyrimidine biosynthesis,0.009670141,3.0,0.009670141,-0.117162146,0.31123897
Pyrimidine catabolism,0.003292935,4.0,0.003292935,-0.21843283,0.19039726
Pyrimidine salvage,0.0012823335,6.0,0.0012823335,-0.25036135,0.08259877
Pyrophosphate hydrolysis,0.00029617053,2.0,0.00029617053,-0.26602176,0.23579597
RA biosynthesis pathway,0.0016248729,14.0,0.0016248729,-0.24492182,-0.24410547
RAB GEFs exchange GTP for GDP on RABs,0.008266356,66.0,0.008266356,-0.1394544,-2.3126655
RAB geranylgeranylation,0.16805346,49.0,0.16805346,2.3979812,0.38185287
RAF activation,0.0030239779,19.0,0.0030239779,-0.22270389,-0.43352842
RAS signaling downstream of NF1 loss-of-function variants,0.030667217,5.0,0.030667217,0.21627356,0.49015266
RET signaling,0.0014134925,24.0,0.0014134925,-0.24827856,-0.66045564
RHO GTPases Activate Formins,0.039550025,71.0,0.039550025,0.35733345,-2.1296792
RHO GTPases Activate NADPH Oxidases,0.0005661819,5.0,0.0005661819,-0.26173392,0.11504599
RHO GTPases Activate ROCKs,0.016845675,14.0,0.016845675,-0.003213935,-0.054430082
RHO GTPases Activate Rhotekin and Rhophilins,3.4164037e-07,6.0,3.4164037e-07,-0.27071956,0.066623114
RHO GTPases Activate WASPs and WAVEs,0.37832505,30.0,0.37832505,5.7371154,3.7882314
RHO GTPases activate CIT,0.03547215,11.0,0.03547215,0.2925764,0.3018002
RHO GTPases activate IQGAPs,0.028571943,12.0,0.028571943,0.18300039,0.17444102
RHO GTPases activate KTN1,0.043368153,11.0,0.043368153,0.4179657,0.40019694
RHO GTPases activate PAKs,0.01503318,16.0,0.01503318,-0.031996544,-0.15975985
RHO GTPases regulate CFTR trafficking,0.006647931,2.0,0.006647931,-0.16515514,0.31494904
RIP-mediated NFkB activation via ZBP1,1.6061309e-05,10.0,1.6061309e-05,-0.2704699,-0.0986674
RMTs methylate histone arginines,0.0005521843,27.0,0.0005521843,-0.26195621,-0.7953037
RNA Pol II CTD phosphorylation and interaction with CE,0.0008409276,22.0,0.0008409276,-0.25737095,-0.5848475
RNA Polymerase I Chain Elongation,8.5473526e-05,20.0,8.5473526e-05,-0.26936764,-0.5115185
RNA Polymerase I Promoter Escape,0.0024925938,20.0,0.0024925938,-0.23114233,-0.48152193
RNA Polymerase I Promoter Opening,5.7136644e-05,3.0,5.7136644e-05,-0.26981762,0.19144568
RNA Polymerase I Transcription Initiation,0.0014806971,22.0,0.0014806971,-0.24721135,-0.5768749
RNA Polymerase I Transcription Termination,2.6801945e-06,21.0,2.6801945e-06,-0.2706824,-0.55392176
RNA Polymerase II Pre-transcription Events,0.0059725456,64.0,0.0059725456,-0.17588034,-2.2585068
RNA Polymerase II Promoter Escape,0.011565672,37.0,0.011565672,-0.08706092,-1.0717742
RNA Polymerase II Transcription Initiation,0.0076456363,37.0,0.0076456363,-0.14931148,-1.1206241
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening,0.0018156605,37.0,0.0018156605,-0.24189208,-1.1932747
RNA Polymerase III Abortive And Retractive Initiation,0.0024586516,27.0,0.0024586516,-0.23168133,-0.77154607
RNA Polymerase III Chain Elongation,0.00021569722,14.0,0.00021569722,-0.26729965,-0.261666
RNA Polymerase III Transcription Initiation From Type 1 Promoter,0.018185977,21.0,0.018185977,0.018070191,-0.327329
RNA Polymerase III Transcription Initiation From Type 2 Promoter,0.0026255231,21.0,0.0026255231,-0.2290314,-0.521237
RNA Polymerase III Transcription Initiation From Type 3 Promoter,0.0011794895,21.0,0.0011794895,-0.25199455,-0.5392568
RNA Polymerase III Transcription Termination,0.022547236,14.0,0.022547236,0.08732742,0.016620416
RNA polymerase II transcribes snRNA genes,0.009718412,50.0,0.009718412,-0.1163956,-1.6326249
RNF mutants show enhanced WNT signaling and proliferation,0.0004451039,5.0,0.0004451039,-0.26365668,0.11353716
ROBO receptors bind AKAP5,0.0037517415,5.0,0.0037517415,-0.21114692,0.15474312
RORA activates gene expression,0.058388058,4.0,0.058388058,0.6564833,0.87697
"ROS, RNS production in phagocytes",0.0026244244,16.0,0.0026244244,-0.22904885,-0.31439266
RPIA deficiency: failed conversion of R5P to RU5P,0.0,1.0,0.0,-0.27072495,0.27347687
RPIA deficiency: failed conversion of RU5P to R5P,0.0,1.0,0.0,-0.27072495,0.27347687
RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),0.00031168718,5.0,0.00031168718,-0.26577532,0.11187458
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known,0.029734636,29.0,0.029734636,0.20146407,-0.5143872
RUNX1 regulates estrogen receptor mediated transcription,0.0010602082,7.0,0.0010602082,-0.25388876,0.038459137
RUNX1 regulates expression of components of tight junctions,0.0047001806,4.0,0.0047001806,-0.19608563,0.20793377
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,0.013662144,29.0,0.013662144,-0.05376874,-0.71467596
RUNX1 regulates transcription of genes involved in BCR signaling,0.020128813,6.0,0.020128813,0.04892262,0.3174558
RUNX1 regulates transcription of genes involved in WNT signaling,0.0031134842,6.0,0.0031134842,-0.22128253,0.10541782
RUNX1 regulates transcription of genes involved in differentiation of HSCs,0.016155822,48.0,0.016155822,-0.014168871,-1.4696612
RUNX1 regulates transcription of genes involved in differentiation of keratinocytes,0.0009027013,7.0,0.0009027013,-0.25638998,0.036496345
RUNX1 regulates transcription of genes involved in differentiation of myeloid cells,0.012122135,6.0,0.012122135,-0.078224234,0.21767989
RUNX1 regulates transcription of genes involved in interleukin signaling,0.012139756,6.0,0.012139756,-0.077944405,0.21789949
RUNX2 regulates bone development,0.028048957,23.0,0.028048957,0.17469531,-0.28716385
RUNX2 regulates genes involved in cell migration,0.02799957,7.0,0.02799957,0.17391105,0.37416634
RUNX2 regulates genes involved in differentiation of myeloid cells,0.002508473,4.0,0.002508473,-0.23089017,0.18062162
RUNX3 Regulates Immune Response and Cell Migration,0.0004094521,3.0,0.0004094521,-0.26422283,0.1958361
RUNX3 regulates BCL2L11 (BIM) transcription,5.513529e-05,4.0,5.513529e-05,-0.2698494,0.15004915
RUNX3 regulates CDKN1A transcription,0.00024170328,6.0,0.00024170328,-0.2668867,0.06963086
RUNX3 regulates NOTCH signaling,0.001131121,11.0,0.001131121,-0.25276265,-0.12614359
RUNX3 regulates RUNX1-mediated transcription,1.0197616e-05,3.0,1.0197616e-05,-0.270563,0.19086076
RUNX3 regulates WNT signaling,0.0028157532,8.0,0.0028157532,-0.22601052,0.018964421
RUNX3 regulates YAP1-mediated transcription,0.00050034944,4.0,0.00050034944,-0.26277936,0.15559721
RUNX3 regulates p14-ARF,0.003871648,6.0,0.003871648,-0.2092428,0.114865735
Rap1 signalling,0.0036152485,9.0,0.0036152485,-0.21331444,-0.012444208
Receptor Mediated Mitophagy,0.0009063485,11.0,0.0009063485,-0.25633207,-0.1289446
Receptor-type tyrosine-protein phosphatases,0.008485494,12.0,0.008485494,-0.13597445,-0.07586802
Recognition and association of DNA glycosylase with site containing an affected purine,3.1775646e-05,3.0,3.1775646e-05,-0.27022037,0.19112962
Recognition and association of DNA glycosylase with site containing an affected pyrimidine,0.007445797,8.0,0.007445797,-0.15248495,0.07666213
Recognition of DNA damage by PCNA-containing replication complex,0.042430036,22.0,0.042430036,0.4030683,-0.06658113
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.00093024934,34.0,0.00093024934,-0.2559525,-1.0801936
Recruitment of NuMA to mitotic centrosomes,0.014651795,58.0,0.014651795,-0.038052976,-1.9021198
Recycling of bile acids and salts,0.05795221,8.0,0.05795221,0.64956206,0.70605224
Recycling of eIF2:GDP,0.007310923,8.0,0.007310923,-0.15462676,0.074981384
Recycling pathway of L1,0.0021077087,21.0,0.0021077087,-0.23725434,-0.52768975
Reduction of cytosolic Ca++ levels,0.011826266,7.0,0.011826266,-0.08292267,0.17262131
Reelin signalling pathway,0.0035882355,5.0,0.0035882355,-0.21374343,0.15270558
Regulated proteolysis of p75NTR,0.003984331,10.0,0.003984331,-0.20745338,-0.049216446
Regulation by TREX1,0.0,1.0,0.0,-0.27072495,0.27347687
Regulation by c-FLIP,0.00041137423,9.0,0.00041137423,-0.26419228,-0.052369565
Regulation of Complement cascade,0.03482508,16.0,0.03482508,0.28230083,0.08687864
Regulation of FZD by ubiquitination,0.0010660266,14.0,0.0010660266,-0.25379634,-0.25106958
Regulation of Glucokinase by Glucokinase Regulatory Protein,0.00996585,25.0,0.00996585,-0.11246625,-0.5952512
Regulation of HSF1-mediated heat shock response,0.006633047,49.0,0.006633047,-0.1653915,-1.6297019
Regulation of IFNA signaling,0.016089203,15.0,0.016089203,-0.015226793,-0.105228536
Regulation of IFNG signaling,0.00012965176,11.0,0.00012965176,-0.2686661,-0.13862348
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.09028028,70.0,0.09028028,1.162935,-1.4561282
Regulation of KIT signaling,0.0024355657,12.0,0.0024355657,-0.23204793,-0.15125974
Regulation of PAK-2p34 activity by PS-GAP/RHG10,0.00011659153,3.0,0.00011659153,-0.26887348,0.1921866
Regulation of PLK1 Activity at G2/M Transition,0.00029920225,61.0,0.00029920225,-0.2659736,-2.2050908
Regulation of PTEN gene transcription,0.013261685,40.0,0.013261685,-0.06012806,-1.174754
Regulation of PTEN localization,0.0064152875,8.0,0.0064152875,-0.16884956,0.06382033
Regulation of PTEN mRNA translation,0.0033942866,10.0,0.0033942866,-0.21682334,-0.056569334
Regulation of PTEN stability and activity,0.017507356,49.0,0.017507356,0.007293618,-1.4941906
Regulation of RAS by GAPs,0.025199221,47.0,0.025199221,0.12944123,-1.3155947
Regulation of RUNX1 Expression and Activity,0.022163516,17.0,0.022163516,0.08123392,-0.112276144
Regulation of RUNX2 expression and activity,0.011175112,47.0,0.011175112,-0.09326305,-1.4903573
Regulation of RUNX3 expression and activity,0.0007261924,34.0,0.0007261924,-0.25919294,-1.0827365
Regulation of TLR by endogenous ligand,0.012867703,8.0,0.012867703,-0.06638454,0.14422768
Regulation of TNFR1 signaling,0.0010524127,22.0,0.0010524127,-0.25401253,-0.58221203
Regulation of TP53 Activity,2.87345e-05,122.0,2.3552869e-07,-0.27072123,-4.732129
Regulation of actin dynamics for phagocytic cup formation,0.020929685,45.0,0.020929685,0.061640553,-1.2860566
Regulation of activated PAK-2p34 by proteasome mediated degradation,3.3448152e-05,33.0,3.3448152e-05,-0.27019382,-1.0499976
Regulation of commissural axon pathfinding by SLIT and ROBO,0.0077366983,6.0,0.0077366983,-0.14786541,0.16303039
Regulation of cortical dendrite branching,0.00071604515,3.0,0.00071604515,-0.25935408,0.19965671
Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,0.007525671,6.0,0.007525671,-0.15121654,0.16040067
Regulation of expression of SLITs and ROBOs,0.00043230664,88.0,0.00043230664,-0.2638599,-3.3204653
Regulation of gene expression by Hypoxia-inducible Factor,0.15675999,7.0,0.15675999,2.2186396,1.9787257
Regulation of gene expression in early pancreatic precursor cells,0.0020256485,2.0,0.0020256485,-0.23855746,0.25734803
Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells,0.001161229,3.0,0.001161229,-0.25228453,0.20520443
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,0.0019466415,4.0,0.0019466415,-0.2398121,0.1736203
Regulation of ornithine decarboxylase (ODC),0.11665107,34.0,0.11665107,1.5817059,0.3618716
Regulation of pyruvate dehydrogenase (PDH) complex,0.0066205855,10.0,0.0066205855,-0.16558939,-0.016364528
Regulation of signaling by CBL,0.0063821995,18.0,0.0063821995,-0.169375,-0.35030803
Regulation of signaling by NODAL,1.25787365e-05,7.0,1.25787365e-05,-0.27052522,0.025403988
Regulation of thyroid hormone activity,0.0003504092,2.0,0.0003504092,-0.2651604,0.2364719
Release of Hh-Np from the secreting cell,0.010172897,5.0,0.010172897,-0.10917833,0.2347609
Release of apoptotic factors from the mitochondria,5.473142e-05,3.0,5.473142e-05,-0.26985583,0.19141573
Removal of aminoterminal propeptides from gamma-carboxylated proteins,0.005824845,6.0,0.005824845,-0.17822583,0.13920568
Repression of WNT target genes,0.048840314,9.0,0.048840314,0.5048642,0.55113184
Resolution of Sister Chromatid Cohesion,0.03213643,60.0,0.03213643,0.23960479,-1.7669768
Retinoid metabolism and transport,0.0013556122,27.0,0.0013556122,-0.2491977,-0.78529173
Retinoid metabolism disease events,0.0,1.0,0.0,-0.27072495,0.27347687
Retrograde neurotrophin signalling,0.0050132577,11.0,0.0050132577,-0.19111393,-0.077766
Retrograde transport at the Trans-Golgi-Network,0.0410541,41.0,0.0410541,0.3812183,-0.86978793
Reuptake of GABA,0.0,1.0,0.0,-0.27072495,0.27347687
Reversible hydration of carbon dioxide,0.019015947,7.0,0.019015947,0.03125021,0.26221615
Rhesus glycoproteins mediate ammonium transport.,2.654467e-05,2.0,2.654467e-05,-0.27030343,0.23243603
Rho GTPase cycle,0.111171745,86.0,0.111171745,1.4946936,-1.8577328
Ribosomal scanning and start codon recognition,0.14331284,31.0,0.14331284,2.0050976,0.81823426
Role of ABL in ROBO-SLIT signaling,0.0015244767,8.0,0.0015244767,-0.24651612,0.0028730612
Role of LAT2/NTAL/LAB on calcium mobilization,0.00055127114,11.0,0.00055127114,-0.26197073,-0.13336945
Role of phospholipids in phagocytosis,0.031782232,14.0,0.031782232,0.2339801,0.13170314
Role of second messengers in netrin-1 signaling,0.00014854479,8.0,0.00014854479,-0.26836607,-0.014273232
S33 mutants of beta-catenin aren't phosphorylated,0.0069165123,12.0,0.0069165123,-0.16089006,-0.09542003
S37 mutants of beta-catenin aren't phosphorylated,0.027693996,12.0,0.027693996,0.1690585,0.16350043
S45 mutants of beta-catenin aren't phosphorylated,0.028196648,12.0,0.028196648,0.17704067,0.16976425
SCF(Skp2)-mediated degradation of p27/p21,0.0046166806,40.0,0.0046166806,-0.19741161,-1.2824844
SDK interactions,0.0,1.0,0.0,-0.27072495,0.27347687
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion,0.0005604682,8.0,0.0005604682,-0.26182467,-0.009140014
SHC-related events triggered by IGF1R,2.7135377e-06,6.0,2.7135377e-06,-0.27068186,0.06665267
SHC1 events in EGFR signaling,0.0011138223,6.0,0.0011138223,-0.25303736,0.08049885
SHC1 events in ERBB2 signaling,0.0013017586,15.0,0.0013017586,-0.25005293,-0.28950357
SHC1 events in ERBB4 signaling,0.00060269336,9.0,0.00060269336,-0.26115412,-0.04998542
SIRT1 negatively regulates rRNA expression,0.00054636924,7.0,0.00054636924,-0.26204857,0.032055877
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs,0.0003706841,7.0,0.0003706841,-0.26483846,0.029866567
SLBP independent Processing of Histone Pre-mRNAs,0.009313479,7.0,0.009313479,-0.12282597,0.141308
SLIT2:ROBO1 increases RHOA activity,0.0077501982,3.0,0.0077501982,-0.14765103,0.28731343
SMAC-mediated apoptotic response,0.0006382689,6.0,0.0006382689,-0.26058918,0.074572705
SMAD2/3 MH2 Domain Mutants in Cancer,0.0012852022,7.0,0.0012852022,-0.25031582,0.04126292
SMAD2/3 Phosphorylation Motif Mutants in Cancer,0.003091091,6.0,0.003091091,-0.22163813,0.105138764
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,0.0011634133,25.0,0.0011634133,-0.25224984,-0.70494354
SMAD4 MH2 Domain Mutants in Cancer,0.0014177776,4.0,0.0014177776,-0.2482105,0.16702984
SRP-dependent cotranslational protein targeting to membrane,0.17587276,51.0,0.17587276,2.5221522,0.39655057
STAT6-mediated induction of chemokines,8.558248e-05,3.0,8.558248e-05,-0.2693659,0.19180018
SUMO is conjugated to E1 (UBA2:SAE1),0.01806468,4.0,0.01806468,0.016143978,0.37447667
SUMO is proteolytically processed,0.023124687,7.0,0.023124687,0.09649742,0.31341758
"SUMO is transferred from E1 to E2 (UBE2I, UBC9)",0.1062052,5.0,0.1062052,1.4158244,1.4314759
SUMOylation of DNA damage response and repair proteins,0.99146885,57.0,0.99146885,15.473901,10.311944
SUMOylation of DNA methylation proteins,0.18039633,10.0,0.18039633,2.5939872,2.1491573
SUMOylation of DNA replication proteins,0.5622389,34.0,0.5622389,8.657685,5.914603
SUMOylation of RNA binding proteins,0.042458136,35.0,0.042458136,0.40351453,-0.6040618
SUMOylation of SUMOylation proteins,0.07693217,29.0,0.07693217,0.9509657,0.07376901
SUMOylation of chromatin organization proteins,0.7053238,41.0,0.7053238,10.929889,7.4080677
SUMOylation of immune response proteins,0.18120994,11.0,0.18120994,2.6069071,2.1179245
SUMOylation of intracellular receptors,0.036729716,21.0,0.036729716,0.31254664,-0.09624457
SUMOylation of transcription cofactors,0.17757636,34.0,0.17757636,2.5492058,1.1210976
SUMOylation of transcription factors,0.19040754,19.0,0.19040754,2.7529662,1.9015684
SUMOylation of ubiquitinylation proteins,0.070340954,32.0,0.070340954,0.84629655,-0.13248277
Scavenging by Class A Receptors,0.014098882,11.0,0.014098882,-0.046833295,0.035455313
Scavenging by Class B Receptors,0.0007910058,3.0,0.0007910058,-0.25816372,0.20059083
Scavenging by Class F Receptors,0.0027711699,5.0,0.0027711699,-0.2267185,0.14252363
Scavenging by Class H Receptors,0.0049383277,3.0,0.0049383277,-0.19230382,0.25227305
Scavenging of heme from plasma,0.0001063279,8.0,0.0001063279,-0.26903647,-0.014799323
SeMet incorporation into proteins,0.000372398,4.0,0.000372398,-0.26481125,0.15400274
Selenocysteine synthesis,0.0002688144,36.0,0.0002688144,-0.26645616,-1.1711793
Sema3A PAK dependent Axon repulsion,0.0029665045,11.0,0.0029665045,-0.22361657,-0.10327178
Sema4D induced cell migration and growth-cone collapse,0.023775643,15.0,0.023775643,0.10683465,-0.0094432905
Sema4D mediated inhibition of cell attachment and migration,0.003256343,6.0,0.003256343,-0.2190139,0.10719806
Senescence-Associated Secretory Phenotype (SASP),0.22390261,33.0,0.22390261,3.2848713,1.7397677
Sensing of DNA Double Strand Breaks,0.0007723909,5.0,0.0007723909,-0.25845933,0.11761567
Serine biosynthesis,0.00224068,8.0,0.00224068,-0.23514274,0.011798105
Serotonin Neurotransmitter Release Cycle,0.008937616,9.0,0.008937616,-0.12879471,0.053880937
Serotonin and melatonin biosynthesis,0.0019135237,3.0,0.0019135237,-0.24033803,0.21457921
Severe congenital neutropenia type 4 (G6PC3),0.0,1.0,0.0,-0.27072495,0.27347687
Signal attenuation,0.07812309,7.0,0.07812309,0.9698777,0.99878496
Signal regulatory protein family interactions,6.6820917e-07,8.0,6.6820917e-07,-0.27071434,-0.016116003
Signal transduction by L1,0.0003383787,14.0,0.0003383787,-0.26535147,-0.26013723
Signaling by BMP,0.0019883665,18.0,0.0019883665,-0.23914951,-0.4050622
Signaling by BRAF and RAF fusions,1.2854345,43.0,1.2854345,20.142103,14.554425
Signaling by FGFR3 fusions in cancer,0.029265042,9.0,0.029265042,0.19400688,0.30719295
Signaling by FGFR3 point mutants in cancer,0.008431081,16.0,0.008431081,-0.13683856,-0.24203251
Signaling by Hippo,4.780876e-05,14.0,4.780876e-05,-0.26996577,-0.26375818
Signaling by Leptin,0.02599616,10.0,0.02599616,0.14209668,0.22508587
Signaling by MST1,0.011333938,2.0,0.011333938,-0.09074088,0.3733441
Signaling by RAS mutants,0.059689797,37.0,0.059689797,0.6771551,-0.47207114
Signaling by high-kinase activity BRAF mutants,0.021528069,22.0,0.021528069,0.07114295,-0.32705283
Signaling by moderate kinase activity BRAF mutants,0.088707685,28.0,0.088707685,1.1379621,0.2618822
Signalling to ERK5,5.839891e-05,3.0,5.839891e-05,-0.26979756,0.19146143
Signalling to ERKs,0.0039347424,22.0,0.0039347424,-0.20824085,-0.5462936
Signalling to STAT3,0.00078101654,3.0,0.00078101654,-0.25832236,0.20046638
Small interfering RNA (siRNA) biogenesis,0.0014495961,7.0,0.0014495961,-0.24770524,0.04331152
Smooth Muscle Contraction,0.01651175,22.0,0.01651175,-0.008516709,-0.38956416
"Sodium-coupled sulphate, di- and tri-carboxylate transporters",1.8409759e-05,3.0,1.8409759e-05,-0.27043262,0.19096309
Sodium/Calcium exchangers,0.009482541,7.0,0.009482541,-0.12014125,0.14341477
Sodium/Proton exchangers,0.011994658,9.0,0.011994658,-0.08024858,0.09197654
Sperm Motility And Taxes,0.016853126,6.0,0.016853126,-0.0030956191,0.27663556
Sperm:Oocyte Membrane Binding,0.0003198454,3.0,0.0003198454,-0.26564577,0.19471946
Sphingolipid de novo biosynthesis,0.027766835,23.0,0.027766835,0.17021519,-0.29067954
Stimulation of the cell death response by PAK-2p34,0.00013083375,3.0,0.00013083375,-0.2686473,0.19236408
Striated Muscle Contraction,0.066167794,27.0,0.066167794,0.7800264,0.022370992
Sulfide oxidation to sulfate,3.2619187e-06,2.0,3.2619187e-06,-0.2706732,0.23214589
Surfactant metabolism,0.030095192,12.0,0.030095192,0.20718972,0.19342314
Synaptic adhesion-like molecules,0.0007642789,17.0,0.0007642789,-0.25858814,-0.37894464
Syndecan interactions,0.015315828,12.0,0.015315828,-0.027508065,0.009248789
Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE),0.0014300137,7.0,0.0014300137,-0.2480162,0.043067504
Synthesis of 12-eicosatetraenoic acid derivatives,0.00028747116,4.0,0.00028747116,-0.2661599,0.15294442
Synthesis of 15-eicosatetraenoic acid derivatives,1.5755892e-05,2.0,1.5755892e-05,-0.27047476,0.2323016
Synthesis of 5-eicosatetraenoic acids,0.00156629,5.0,0.00156629,-0.24585213,0.12750892
Synthesis of BMP,0.0,1.0,0.0,-0.27072495,0.27347687
Synthesis of CL,0.0006417864,2.0,0.0006417864,-0.26053333,0.2401029
Synthesis of Hepoxilins (HX) and Trioxilins (TrX),7.5040036e-05,2.0,7.5040036e-05,-0.2695333,0.23304038
"Synthesis of IP2, IP, and Ins in the cytosol",0.015511921,12.0,0.015511921,-0.024394091,0.011692417
Synthesis of IP3 and IP4 in the cytosol,0.0015270534,18.0,0.0015270534,-0.2464752,-0.41081086
Synthesis of IPs in the ER lumen,0.0,1.0,0.0,-0.27072495,0.27347687
Synthesis of IPs in the nucleus,0.0006205672,4.0,0.0006205672,-0.2608703,0.15709531
Synthesis of Ketone Bodies,0.045393065,5.0,0.045393065,0.4501215,0.6736601
Synthesis of Leukotrienes (LT) and Eoxins (EX),0.0007220601,11.0,0.0007220601,-0.25925857,-0.13124114
Synthesis of Lipoxins (LX),0.0026780302,3.0,0.0026780302,-0.22819757,0.22410618
Synthesis of PA,0.06729978,22.0,0.06729978,0.7980024,0.24333541
Synthesis of PC,0.07648494,19.0,0.07648494,0.9438637,0.48191184
Synthesis of PE,0.023727855,11.0,0.023727855,0.10607577,0.1554476
Synthesis of PG,0.24059805,7.0,0.24059805,3.5499966,3.0234811
Synthesis of PI,0.00278843,6.0,0.00278843,-0.22644441,0.101367116
Synthesis of PIPs at the ER membrane,0.015885254,6.0,0.015885254,-0.018465515,0.26457435
Synthesis of PIPs at the Golgi membrane,0.012405632,13.0,0.012405632,-0.07372227,-0.06838848
Synthesis of PIPs at the early endosome membrane,0.04119619,14.0,0.04119619,0.3834747,0.24901599
Synthesis of PIPs at the late endosome membrane,0.0024498322,10.0,0.0024498322,-0.23182139,-0.06833875
Synthesis of PIPs at the plasma membrane,0.03248544,44.0,0.03248544,0.24514712,-1.1006819
Synthesis of PIPs in the nucleus,0.0025295955,4.0,0.0025295955,-0.23055474,0.18088484
Synthesis of PS,0.0,1.0,0.0,-0.27072495,0.27347687
Synthesis of Prostaglandins (PG) and Thromboxanes (TX),0.0039660353,9.0,0.0039660353,-0.20774393,-0.008072855
Synthesis of active ubiquitin: roles of E1 and E2 enzymes,0.093657225,23.0,0.093657225,1.2165613,0.53041935
Synthesis of bile acids and bile salts,0.007423758,15.0,0.007423758,-0.15283492,-0.21321374
Synthesis of diphthamide-EEF2,0.015110193,8.0,0.015110193,-0.03077357,0.17217268
Synthesis of dolichyl-phosphate mannose,2.174719e-10,2.0,2.174719e-10,-0.27072495,0.23210524
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET),0.000112318274,5.0,0.000112318274,-0.26894134,0.10939012
Synthesis of glycosylphosphatidylinositol (GPI),0.018483814,13.0,0.018483814,0.022799874,0.0073553254
Synthesis of pyrophosphates in the cytosol,0.009035704,6.0,0.009035704,-0.12723708,0.17921808
Synthesis of very long-chain fatty acyl-CoAs,0.0061862217,14.0,0.0061862217,-0.17248714,-0.1872638
Synthesis of wybutosine at G37 of tRNA(Phe),0.0059749535,3.0,0.0059749535,-0.17584209,0.26519105
"Synthesis, secretion, and deacylation of Ghrelin",0.00029089782,7.0,0.00029089782,-0.26610547,0.028872302
"Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)",0.008479213,8.0,0.008479213,-0.1360742,0.08954014
"Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)",0.00016538944,8.0,0.00016538944,-0.26809856,-0.014063305
T41 mutants of beta-catenin aren't phosphorylated,0.15202187,12.0,0.15202187,2.1433978,1.7128233
TAK1 activates NFkB by phosphorylation and activation of IKKs complex,0.0015828703,17.0,0.0015828703,-0.24558882,-0.3687437
"TALDO1 deficiency: failed conversion of  Fru(6)P, E4P to SH7P, GA3P",0.0,1.0,0.0,-0.27072495,0.27347687
"TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P",0.0,1.0,0.0,-0.27072495,0.27347687
TBC/RABGAPs,0.0011312354,30.0,0.0011312354,-0.25276086,-0.9122026
TCF7L2 mutants don't bind CTBP,1.998073e-05,3.0,1.998073e-05,-0.27040768,0.19098265
"TET1,2,3 and TDG demethylate DNA",0.00045640994,4.0,0.00045640994,-0.26347715,0.15504964
TFAP2 (AP-2) family regulates transcription of cell cycle factors,0.0006520709,5.0,0.0006520709,-0.26037002,0.11611631
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,0.005074828,9.0,0.005074828,-0.19013618,0.005744462
TFAP2 (AP-2) family regulates transcription of other transcription factors,7.33216e-05,2.0,7.33216e-05,-0.2695606,0.23301893
TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation,5.9185095e-05,4.0,5.9185095e-05,-0.2697851,0.1500996
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),0.00079166034,13.0,0.00079166034,-0.25815332,-0.21311705
TGFBR1 KD Mutants in Cancer,0.00019294473,6.0,0.00019294473,-0.267661,0.06902324
TGFBR1 LBD Mutants in Cancer,0.00090213446,3.0,0.00090213446,-0.25639898,0.20197569
TGFBR2 Kinase Domain Mutants in Cancer,0.0026484134,3.0,0.0026484134,-0.2286679,0.2237371
TGFBR2 MSI Frameshift Mutants in Cancer,7.3973075e-05,2.0,7.3973075e-05,-0.26955026,0.23302706
TICAM1 deficiency - HSE,8.874164e-06,2.0,8.874164e-06,-0.27058405,0.23221584
"TICAM1, RIP1-mediated IKK complex recruitment ",0.004783405,14.0,0.004783405,-0.194764,-0.20474514
"TICAM1,TRAF6-dependent induction of TAK1 complex",0.00038539336,11.0,0.00038539336,-0.2646049,-0.13543653
TICAM1-dependent activation of IRF3/IRF7,0.00024496985,10.0,0.00024496985,-0.26683483,-0.095814824
TLR3 deficiency - HSE,2.691288e-06,2.0,2.691288e-06,-0.27068222,0.23213877
TLR3-mediated TICAM1-dependent programmed cell death,0.0007512108,6.0,0.0007512108,-0.25879568,0.075980134
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,0.0049936306,9.0,0.0049936306,-0.1914256,0.004732622
TNFR1-induced NFkappaB signaling pathway,0.0013222483,12.0,0.0013222483,-0.24972752,-0.16513343
TNFR1-induced proapoptotic signaling,0.008731404,4.0,0.008731404,-0.13206938,0.2581692
TNFR1-mediated ceramide production,0.0005867714,2.0,0.0005867714,-0.26140696,0.23941736
TNFs bind their physiological receptors,0.017698249,9.0,0.017698249,0.010325021,0.16305234
TP53 Regulates Metabolic Genes,0.010818539,54.0,0.010818539,-0.098925464,-1.784402
TP53 Regulates Transcription of Cell Cycle Genes,0.005692767,29.0,0.005692767,-0.18032324,-0.8139871
TP53 Regulates Transcription of Cell Death Genes,5.0059843e-05,31.0,5.0059843e-05,-0.26993,-0.96704733
TP53 Regulates Transcription of DNA Repair Genes,0.013890466,49.0,0.013890466,-0.050142962,-1.5392628
TRAF3 deficiency - HSE,6.3474763e-06,3.0,6.3474763e-06,-0.27062416,0.19081277
TRAF3-dependent IRF activation pathway,0.00086738745,12.0,0.00086738745,-0.25695077,-0.17080173
TRAF6 mediated IRF7 activation,0.0035359638,18.0,0.0035359638,-0.2145735,-0.38577664
TRAF6 mediated NF-kB activation,0.0058779106,14.0,0.0058779106,-0.17738315,-0.19110586
TRAIL  signaling,0.0034603686,7.0,0.0034603686,-0.21577397,0.068368934
TRP channels,0.0072380425,11.0,0.0072380425,-0.15578412,-0.050041642
TWIK related potassium channel (TREK),0.0,1.0,0.0,-0.27072495,0.27347687
TWIK-related alkaline pH activated K+ channel (TALK),0.0045630033,3.0,0.0045630033,-0.198264,0.24759594
TWIK-related spinal cord K+ channel (TRESK),8.2945386e-13,2.0,8.2945386e-13,-0.27072495,0.23210524
TWIK-releated acid-sensitive K+ channel (TASK),0.0,1.0,0.0,-0.27072495,0.27347687
TYSND1 cleaves peroxisomal proteins,0.40712014,6.0,0.40712014,6.194384,5.139982
Tandem of pore domain in a weak inwardly rectifying K+ channels (TWIK),0.012683364,3.0,0.012683364,-0.069311865,0.3487885
Tandem pore domain halothane-inhibited K+ channel (THIK),0.0,1.0,0.0,-0.27072495,0.27347687
Telomere C-strand (Lagging Strand) Synthesis,2.5792478e-05,17.0,2.5792478e-05,-0.27031538,-0.38814735
Telomere Extension By Telomerase,0.00047613287,3.0,0.00047613287,-0.26316392,0.19666703
Terminal pathway of complement,0.015935825,4.0,0.015935825,-0.017662445,0.34794775
Termination of O-glycan biosynthesis,0.0023712567,10.0,0.0023712567,-0.23306917,-0.069317915
Termination of translesion DNA synthesis,0.0274373,22.0,0.0274373,0.16498214,-0.25341445
"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.000715504,8.0,0.000715504,-0.2593627,-0.0072080167
The AIM2 inflammasome,0.0030585672,2.0,0.0030585672,-0.2221546,0.27021983
The IPAF inflammasome,0.0006816591,3.0,0.0006816591,-0.25990015,0.19922823
The NLRP1 inflammasome,0.0077060447,3.0,0.0077060447,-0.1483522,0.2867632
The NLRP3 inflammasome,0.02387339,9.0,0.02387339,0.1083869,0.2400044
The activation of arylsulfatases,0.0012976326,6.0,0.0012976326,-0.25011843,0.08278941
The fatty acid cycling model,0.00088225974,3.0,0.00088225974,-0.25671458,0.20172803
The proton buffering model,0.0012677903,3.0,0.0012677903,-0.25059232,0.20653233
The role of GTSE1 in G2/M progression after G2 checkpoint,0.00013878277,37.0,0.00013878277,-0.2685211,-1.2141714
The role of Nef in HIV-1 replication and disease pathogenesis,0.0031664185,24.0,0.0031664185,-0.22044192,-0.6386114
Threonine catabolism,0.020003019,3.0,0.020003019,0.046925005,0.44000304
Thrombin signalling through proteinase activated receptors (PARs),0.015300691,24.0,0.015300691,-0.02774844,-0.48739907
Thromboxane signalling through TP receptor,8.825897e-05,18.0,8.825897e-05,-0.2693234,-0.42874053
Tie2 Signaling,0.0061612157,12.0,0.0061612157,-0.17288424,-0.10483222
Tight junction interactions,0.0010570807,18.0,0.0010570807,-0.2539384,-0.41666746
Tolerance by Mtb to nitric oxide produced by macrophages,0.0,1.0,0.0,-0.27072495,0.27347687
Tolerance of reactive oxygen produced by macrophages,0.0,1.0,0.0,-0.27072495,0.27347687
Toxicity of botulinum toxin type A (BoNT/A),0.0023324627,3.0,0.0023324627,-0.23368523,0.21979988
Toxicity of botulinum toxin type B (BoNT/B),0.002902469,2.0,0.002902469,-0.22463347,0.2682746
Toxicity of botulinum toxin type C (BoNT/C),0.0012136112,4.0,0.0012136112,-0.25145268,0.16448559
Toxicity of botulinum toxin type D (BoNT/D),0.0095836315,4.0,0.0095836315,-0.11853593,0.26878932
Toxicity of botulinum toxin type E (BoNT/E),0.021041334,3.0,0.021041334,0.063413545,0.45294207
Toxicity of botulinum toxin type F (BoNT/F),1.4629763e-05,4.0,1.4629763e-05,-0.27049264,0.14954437
Toxicity of botulinum toxin type G (BoNT/G),0.0010534736,3.0,0.0010534736,-0.25399572,0.20386161
Toxicity of tetanus toxin (TeNT),0.0019640645,2.0,0.0019640645,-0.23953542,0.2565806
Trafficking and processing of endosomal TLR,0.0012900569,9.0,0.0012900569,-0.25023875,-0.041419785
Trafficking of AMPA receptors,0.032276586,19.0,0.032276586,0.24183048,-0.06899445
Trafficking of myristoylated proteins to the cilium,0.003756475,6.0,0.003756475,-0.21107176,0.11343049
Transcription of E2F targets under negative control by DREAM complex,0.13379464,12.0,0.13379464,1.8539474,1.4856828
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1,0.011135307,6.0,0.011135307,-0.09389516,0.20538245
Transcriptional Regulation by E2F6,0.0008343155,23.0,0.0008343155,-0.25747594,-0.62630147
Transcriptional activation of mitochondrial biogenesis,1.3978153e-05,22.0,1.3978153e-05,-0.270503,-0.5951526
Transcriptional regulation by small RNAs,0.0006402132,35.0,0.0006402132,-0.2605583,-1.1251795
Transcriptional regulation of white adipocyte differentiation,0.004064808,40.0,0.004064808,-0.2061754,-1.2893617
Transfer of LPS from LBP carrier to CD14,1.4216034e-05,2.0,1.4216034e-05,-0.27049923,0.23228239
Transferrin endocytosis and recycling,0.007085251,19.0,0.007085251,-0.15821047,-0.3829185
Translesion Synthesis by POLH,0.0030277309,12.0,0.0030277309,-0.2226443,-0.14388041
Translesion synthesis by POLI,0.003986232,12.0,0.003986232,-0.2074232,-0.13193597
Translesion synthesis by POLK,0.052994482,12.0,0.052994482,0.5708328,0.47878462
Translesion synthesis by REV1,0.014312934,11.0,0.014312934,-0.04343412,0.038122743
Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0069391006,39.0,0.0069391006,-0.16053136,-1.2121718
Translocation of ZAP-70 to Immunological synapse,0.0012938704,3.0,0.0012938704,-0.2501782,0.20685732
Transport and synthesis of PAPS,0.0332646,5.0,0.0332646,0.25752026,0.5225202
Transport of Mature mRNA Derived from an Intronless Transcript,0.0005238305,11.0,0.0005238305,-0.2624065,-0.1337114
Transport of Mature mRNA derived from an Intron-Containing Transcript,0.018622866,62.0,0.018622866,0.025008034,-2.0181205
Transport of Ribonucleoproteins into the Host Nucleus,0.00073606044,3.0,0.00073606044,-0.25903627,0.19990614
Transport of fatty acids,0.0005666142,4.0,0.0005666142,-0.26172706,0.156423
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus,0.0021952542,5.0,0.0021952542,-0.2358641,0.13534681
Transport of glycerol from adipocytes to the liver by Aquaporins,0.0,1.0,0.0,-0.27072495,0.27347687
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane,0.032399494,4.0,0.032399494,0.24378228,0.5531112
Transport of nucleotide sugars,0.0014142031,9.0,0.0014142031,-0.24826726,-0.039872717
Transport of organic anions,0.023809252,5.0,0.023809252,0.10736837,0.40469152
Transport of the SLBP Dependant Mature mRNA,0.013053227,6.0,0.013053227,-0.06343839,0.22928278
Transport of the SLBP independent Mature mRNA,0.00037649844,6.0,0.00037649844,-0.26474613,0.071310624
Triglyceride biosynthesis,0.12117585,8.0,0.12117585,1.6535598,1.4939191
Triglyceride catabolism,0.37867257,18.0,0.37867257,5.742634,4.289021
"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.0011942501,11.0,0.0011942501,-0.25176015,-0.12535691
Truncations of AMER1 destabilize the destruction complex,0.0062431158,11.0,0.0062431158,-0.17158367,-0.06244002
Tryptophan catabolism,9.9875515e-06,6.0,9.9875515e-06,-0.27056637,0.06674332
Type I hemidesmosome assembly,0.0012992417,4.0,0.0012992417,-0.25009286,0.16555268
Type II Na+/Pi cotransporters,0.00039069168,2.0,0.00039069168,-0.26452073,0.2369739
UCH proteinases,0.17130971,62.0,0.17130971,2.4496906,-0.11539994
UNC93B1 deficiency - HSE,2.2869393e-05,2.0,2.2869393e-05,-0.27036178,0.23239024
Ub-specific processing proteases,0.018957965,121.0,0.0001566774,-0.2682369,-4.4548693
Ubiquinol biosynthesis,0.029939247,5.0,0.029939247,0.20471331,0.481081
Ubiquitin-dependent degradation of Cyclin D1,0.0131984865,35.0,0.0131984865,-0.06113166,-0.9686835
"Unblocking of NMDA receptor, glutamate binding and activation",0.019671347,12.0,0.019671347,0.04165802,0.063525476
Unwinding of DNA,3.683135e-06,9.0,3.683135e-06,-0.27066648,-0.05745006
Uptake and function of anthrax toxins,0.010932438,7.0,0.010932438,-0.09711674,0.16148278
Uptake and function of diphtheria toxin,0.0007179351,3.0,0.0007179351,-0.2593241,0.19968025
Urea cycle,0.0001395405,3.0,0.0001395405,-0.26850906,0.19247256
Utilization of Ketone Bodies,0.006124914,3.0,0.006124914,-0.17346072,0.26705983
VEGF binds to VEGFR leading to receptor dimerization,0.00078970124,6.0,0.00078970124,-0.25818443,0.076459795
VEGFR2 mediated cell proliferation,0.0023312552,13.0,0.0023312552,-0.2337044,-0.1939312
VEGFR2 mediated vascular permeability,0.058749508,21.0,0.058749508,0.66222316,0.17815706
VLDL assembly,0.0,1.0,0.0,-0.27072495,0.27347687
VLDL clearance,0.0001947997,3.0,0.0001947997,-0.26763153,0.19316117
VLDLR internalisation and degradation,0.0013168291,8.0,0.0013168291,-0.24981359,0.00028545066
Variant SLC6A14 may confer susceptibility towards obesity,0.0,1.0,0.0,-0.27072495,0.27347687
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.27072495,0.27347687
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.27072495,0.27347687
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.27072495,0.27347687
Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG),0.0,1.0,0.0,-0.27072495,0.27347687
Vasopressin regulates renal water homeostasis via Aquaporins,0.00071552146,27.0,0.00071552146,-0.2593624,-0.7932682
Vif-mediated degradation of APOBEC3G,0.00047728306,35.0,0.00047728306,-0.2631457,-1.1272099
Virus Assembly and Release,0.0,1.0,0.0,-0.27072495,0.27347687
Vitamin B1 (thiamin) metabolism,0.000106468025,6.0,0.000106468025,-0.26903424,0.06794562
Vitamin B2 (riboflavin) metabolism,0.29974583,6.0,0.29974583,4.4892693,3.801928
Vitamin C (ascorbate) metabolism,0.001035407,4.0,0.001035407,-0.2542826,0.16226488
Vitamin D (calciferol) metabolism,0.04888443,9.0,0.04888443,0.50556475,0.55168164
Vitamin E,6.5303375e-06,2.0,6.5303375e-06,-0.27062127,0.23218663
Vitamins,0.0018171616,3.0,0.0018171616,-0.24186826,0.21337838
Vitamins B6 activation to pyridoxal phosphate,0.00074937753,2.0,0.00074937753,-0.25882477,0.24144368
Voltage gated Potassium channels,0.0013386523,18.0,0.0013386523,-0.24946705,-0.41315866
Vpu mediated degradation of CD4,0.000926735,34.0,0.000926735,-0.25600833,-1.0802374
VxPx cargo-targeting to cilium,0.01461605,18.0,0.01461605,-0.038620614,-0.24770118
WNT ligand biogenesis and trafficking,0.0049335156,13.0,0.0049335156,-0.19238023,-0.16150291
WNT ligand secretion is abrogated by the PORCN inhibitor LGK974,0.0,1.0,0.0,-0.27072495,0.27347687
WNT mediated activation of DVL,0.021580346,7.0,0.021580346,0.071973115,0.2941726
"WNT5A-dependent internalization of FZD2, FZD5 and ROR2",0.00051800505,4.0,0.00051800505,-0.26249897,0.15581723
WNT5A-dependent internalization of FZD4,0.014341453,9.0,0.014341453,-0.042981237,0.121221334
Wax biosynthesis,0.011848007,3.0,0.011848007,-0.08257741,0.33837864
"XAV939 inhibits tankyrase, stabilizing AXIN",0.0034994439,3.0,0.0034994439,-0.21515344,0.23434229
XBP1(S) activates chaperone genes,2.6321206e-06,33.0,2.6321206e-06,-0.27068317,-1.0503815
Xenobiotics,0.0027920872,8.0,0.0027920872,-0.22638634,0.018669516
YAP1- and WWTR1 (TAZ)-stimulated gene expression,0.0145747615,7.0,0.0145747615,-0.039276276,0.2068719
Zinc transporters,0.13749346,9.0,0.13749346,1.9126852,1.6558911
alpha-linolenic acid (ALA) metabolism,0.01136203,8.0,0.01136203,-0.09029477,0.1254646
c-src mediated regulation of Cx43 function and closure of gap junctions,0.001667588,3.0,0.001667588,-0.2442435,0.21151446
cGMP effects,0.0014420048,5.0,0.0014420048,-0.24782579,0.12596013
eNOS activation,0.0017032229,10.0,0.0017032229,-0.2436776,-0.07764267
mRNA 3'-end processing,0.08633506,49.0,0.08633506,1.1002846,-0.63648814
mRNA Capping,0.00010987407,24.0,0.00010987407,-0.26898015,-0.6767008
mRNA Splicing - Major Pathway,0.0048634293,139.0,3.49887e-05,-0.27016935,-5.375198
mRNA Splicing - Minor Pathway,0.048574936,38.0,0.048574936,0.5006499,-0.6519516
mRNA decay by 3' to 5' exoribonuclease,0.012042087,14.0,0.012042087,-0.07949541,-0.11429043
mRNA decay by 5' to 3' exoribonuclease,0.01341965,12.0,0.01341965,-0.057619568,-0.014380605
mTORC1-mediated signalling,0.005400126,12.0,0.005400126,-0.18497042,-0.114316605
mitochondrial fatty acid beta-oxidation of saturated fatty acids,0.45243073,9.0,0.45243073,6.913921,5.580509
mitochondrial fatty acid beta-oxidation of unsaturated fatty acids,0.15745106,2.0,0.15745106,2.229614,2.1941955
p130Cas linkage to MAPK signaling for integrins,0.0059112483,11.0,0.0059112483,-0.17685375,-0.06657561
p53-Dependent G1 DNA Damage Response,0.0024862518,42.0,0.0024862518,-0.23124304,-1.3917761
p53-Independent DNA Damage Response,0.0016470721,35.0,0.0016470721,-0.2445693,-1.1126324
p75NTR negatively regulates cell cycle via SC1,0.007755202,5.0,0.007755202,-0.14757158,0.20463257
p75NTR recruits signalling complexes,0.01423848,10.0,0.01423848,-0.044616465,0.07856653
rRNA modification in the mitochondrion,0.0040766746,5.0,0.0040766746,-0.20598696,0.1587923
rRNA modification in the nucleus and cytosol,0.0025468124,41.0,0.0025468124,-0.23028132,-1.3496499
snRNP Assembly,0.030785399,12.0,0.030785399,0.21815029,0.20202419
tRNA modification in the mitochondrion,0.0015570059,6.0,0.0015570059,-0.24599956,0.08602162
tRNA processing in the mitochondrion,1.8062706e-06,2.0,1.8062706e-06,-0.27069628,0.23212776
tRNA processing in the nucleus,0.0021905545,41.0,0.0021905545,-0.23593874,-1.3540895
via Dependence Receptors in the absence of ligand,0.0001594147,10.0,0.0001594147,-0.26819345,-0.09688097
